

AD _____

Award Number: DAMD17-97-1-7014

TITLE: A New Invasion and Metastasis Molecule, Tiam1 and its
Interaction with the Cytoskeleton are Involved in Human
Breast Cancer Progression

PRINCIPAL INVESTIGATOR: Lilly Y.W. Bourguignon, Ph.D.

CONTRACTING ORGANIZATION: University of Miami
Miami, Florida 33101

REPORT DATE: August 2000

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are
those of the author(s) and should not be construed as an official
Department of the Army position, policy or decision unless so
designated by other documentation.

20010403 047

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE August 2000		3. REPORT TYPE AND DATES COVERED Annual (7 Jul 99 - 6 Jul 00)	
4. TITLE AND SUBTITLE A New Invasion and Metastasis Molecule, Tiam1 and its Interaction with the Cytoskeleton are Involved in Human Breast Cancer Progression				5. FUNDING NUMBERS DAMD17-97-1-7014	
6. AUTHOR(S) Lilly Y.W. Bourguignon, Ph.D.					
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Miami Miami, Florida 33101 E-MAIL: lbουργui@med.miami.edu				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES					
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited					12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) Tiam1 (T lymphoma invasion and metastasis) is one of the known guanine nucleotide (GDP/GTP) exchange factors (GEFs) for RhoGTPases (e.g. Rac1) and is expressed in breast tumor cells (e.g. SP-1 cell line). Immunoprecipitation and immunoblot analyses indicate that Tiam1 and the cytoskeletal protein, ankyrin, are physically associated as a complex <i>in vivo</i> . In particular, the ankyrin repeat domain (ARD) of ankyrin is responsible for Tiam1 binding. Biochemical analyses indicate that the 11aa sequence between aa717 and aa727 of Tiam1 (⁷¹⁷ GEGTDAVKRS ⁷²⁷ L) is the ankyrin binding domain. Most importantly, ankyrin binding to Tiam1 activates GDP/GTP exchange on RhoGTPases (e.g. Rac1). Using an <i>Escherichia coli</i> -derived calmodulin-binding peptide (CBP)-tagged recombinant Tiam1 (aa393-aa728) fragment which contains the ankyrin-binding domain, we have detected a specific binding interaction between the Tiam1 (aa393-aa738) fragment and ankyrin <i>in vitro</i> . This Tiam1 fragment also acts as a potent competitive inhibitor for Tiam1 binding to ankyrin. Transfection of SP-1 cell with Tiam1 cDNAs stimulates (i) Tiam1-ankyrin association in the membrane projections, (ii) Rac1 activation and (iii) breast tumor cell invasion and migration. Co-transfection of SP1 cells with green fluorescent protein (GFP)-tagged Tiam1 fragment cDNA and Tiam1 cDNA effectively blocks Tiam1-ankyrin co-localization in the cell membrane and inhibits GDP/GTP exchange on Rac1 by ankyrin-associated Tiam1 and tumor-specific phenotypes. These findings suggest that ankyrin-Tiam1 interaction plays a pivotal role in regulating Rac1 signaling and cytoskeleton function required for oncogenic signaling and metastatic breast tumor cell progression.					
14. SUBJECT TERMS Breast Cancer				15. NUMBER OF PAGES 41	
				16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited		

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

___ Where copyrighted material is quoted, permission has been obtained to use such material.

___ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

___ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

X In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

X For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

X In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

X In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

N/A In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.



PI - Signature 7/10/00
Date

Table of Contents

Cover.....	1
SF 298.....	2
Foreword.....	3
Table of Contents.....	4
Introduction.....	5-6
Body.....	6-17
Key Research Accomplishments.....	17-18
Reportable Outcomes.....	18
Conclusions.....	19-21
References.....	21-25
Appendices.....	26-38
Final Reports.....	39-41

INTRODUCTION

Members of the Rho subclass of the ras superfamily [small molecular weight GTPases, (e.g. RhoA, Rac1 and Cdc42)] are known to be associated with changes in the membrane-linked cytoskeleton (Ridley and Hall, 1992; Hall, 1998). For example, activation of RhoA, Rac1 and Cdc42 have been shown to produce specific structural changes in the plasma membrane-cytoskeleton associated with membrane ruffling, lamellipodia, filopodia, and stress fiber formation (Ridley and Hall, 1992; Hall, 1998). The coordinated activation of these GTPases is thought to be a possible mechanism underlying cell motility, an obvious prerequisite for metastasis (Dickson and Lippman, 1995; Jiang et al., 1994; Lauffenburger and Horwitz, 1996).

Several guanine nucleotide exchange factors (GEFs - the dbl or DH family) have been identified as oncogenes due to their ability to up regulate Rho GTPase activity during malignant transformation (van Aelst and D'Souza-Schorey, 1997). One of these GEFs is Tiam1 (T lymphoma invasion and metastasis) which was identified by retroviral insertional mutagenesis and selected for its invasive cell behavior *in vitro* (Habets et al., 1994; Habets et al., 1995). This molecule is largely hydrophilic and contains several functional domains found in signal transduction proteins. For example, the C-terminal region of the Tiam1 molecule has a Dbl homology (DH) domain (Habets et al., 1994; Hart et al., 1991; Hart et al., 1994) and an adjacent pleckstrin homology (PH) domain which exists in most GEFs (Habets et al., 1994; Hart et al., 1991; Hart et al., 1994; Lemmon et al., 1996). In particular, the DH domain of these proteins exhibits GDP/GTP exchange activity for specific members of the Ras superfamily of GTP-binding proteins (Hart et al., 1991; Hart et al., 1994). Tiam1 also contains an additional PH domain, a Discs-large homology region (DHR) (Habets et al., 1994; Pontings and Phillips, 1995) and a potential myristoylation site in the N-terminal part of the protein (Habets et al., 1994).

Overexpression of both N- and C-terminally truncated, as well as full-length, Tiam1 proteins induces the invasive phenotype in otherwise noninvasive lymphoma cell lines (Michiels et al., 1995). It is also well-established that Tiam1 is capable of activating Rac1 *in vitro* as a GEF and induces membrane cytoskeleton-mediated cell shape changes, cell adhesion and cell motility (Michiels et al., 1995; Woods and Bryant 1991; van Leeuwen et al., 1995; Nobes and Hall, 1995). These findings have prompted investigations into the mechanisms involved in the regulation of Tiam1. In fact, it has been found that addition of certain serum-derived lipids [e.g. sphingosine-1-phosphate (S1P) and LPA] to T-lymphoma cells promotes Tiam1-mediated Rac1 signaling and T-lymphoma cell invasion (Stam et al., 1998). A Tiam1 transcript has been detected in breast cancer cells (Habets et al., 1995). Tiam1 is shown to function as a GEF in activating Rac1 signaling in breast tumor cells (Bourguignon, et al., 2000). The question of how this molecule is regulated in invasive and metastatic processes of breast cancer cells is addressed in the present study.

Ankyrin belongs to a family of cytoskeletal proteins that mediate linkage of integral membrane proteins with the spectrin-based skeleton in regulating a variety of biological activities (Bennett, 1992; Bennett and Gilligan, 1993; De Matteis and Morrow, 1998). Presently, at least three ankyrin genes have been identified: ankyrin 1 (ANK 1 or ankyrin R), ankyrin 2 (ANK 2 or ankyrin B) and ankyrin 3 (ANK 3 or ankyrin G) (Lambert, et al., 1990; Lux et al., 1990; Tse, et al., 1991; Otto, et al., 1991; Kordeli, et al., 1995; Peters, et al., 1995; Peters and Lux 1993). All ankyrin species (e.g. ANK 1, ANK 2 and ANK 3) are monomers comprised of two highly conserved domains and a variable domain. Both conserved domains are located in the N-terminal region and include a membrane-binding site [M. Wt. \approx 89-95kDa, also called the ankyrin repeat domain (ARD)] (Lux et al., 1990; Davis and Bennet, 1990), and a spectrin binding domain (SBD) (M.Wt. \approx 62kDa) (Platt,

et al., 1993). The striking feature shared by all three forms of ankyrins is the repeated 33-amino acid motif present in 24 contiguous copies within the ARD. The ARD of ANK 1, ANK 2 and ANK 3 is highly conserved. A number of tumor cells express ankyrin such as ANK1 and ANK3 (Bourguignon, et al., 1998b; Bourguignon, et al., 1999a; Zhu and Bourguignon, 2000). Most recently, we have found that ankyrin's ARD interacts with the adhesion molecule, CD44 and promotes tumor cell migration (Zhu and Bourguignon, 2000). In addition, the ARD domain (also referred to as cdc 10 repeats, cdc10/SW16 repeats, and SW16/ANK repeats) has been detected in a number of functionally distinct proteins participating in protein-protein binding and protein-DNA interactions (Lux, et al. 1990; Davis and Bennet, 1990).

In this study we have focused on the regulatory aspect of Tiam1-Rac1 signaling in metastatic breast tumor cells (SP-1 cell line). Our results indicate that Tiam1 interacts with ankyrin *in vivo* and *in vitro*. In particular, the ankyrin repeat domain (ARD) is directly involved in Tiam1 binding. Biochemical analyses show that the Tiam1 fragment (aa393-aa738) contains an ankyrin-binding site and competes for Tiam1 binding to ankyrin. Most importantly, the binding of ankyrin [in particular, ankyrin repeat domain (ARD)] to Tiam1 activates Rho-like GTPase such as Rac1. Overexpression of Tiam1 in SP-1 cells by transfecting Tiam1 cDNA induces Tiam1-ankyrin association in the cell membrane, Rac1 signaling and metastatic phenotypes. Both Tiam1-ankyrin interaction and tumor-specific behaviors are significantly inhibited by co-transfecting SP-1 cells with the Tiam1 (aa393-aa738) fragment cDNA and Tiam1 cDNA. Our observations suggest that Tiam1 interaction with ankyrin promotes RhoGTPase activation and cytoskeletal changes required for metastatic breast tumor cell invasion and migration.

BODY

MATERIALS AND METHODS

Cell Culture: Mouse breast tumor cells (e.g. SP1 cell line) (provided by Dr. Bruce Elliott, Department of Pathology, and Biochemistry, Queen's University, Kingston, Ontario, Canada) were used in this study. Specifically, SP1 cell line was derived from a spontaneous intraductal mammary adenocarcinoma that arose in a retired female CBA/J breeder in the Queen's University animal colony. These cells were capable of inducing lung metastases by sequential passage of SP1 cells into mammary gland (Elliott, et al., 1988). These cells were cultured in RPMI1640 medium supplemented with either 5% or 20% fetal calf serum, folic acid (290mg/L), and sodium pyruvate (100mg/L).

COS-7 cells were obtained from American Type Culture Collection and grown routinely in Dulbecco's Modified Eagle's Medium (DMEM) containing 10% fetal bovine serum, 1% glutamine, 1% penicillin and 1% streptomycin.

Antibodies and Reagents: For the preparation of polyclonal rabbit anti-Tiam1 antibody, specific synthetic peptides [\approx 15-17 amino acids unique for the C-terminal sequence of Tiam1] were prepared by the Peptide Laboratories of Department of Biochemistry and Molecular Biology using an Advanced Chemtech automatic synthesizer (model ACT350). These Tiam1-related polypeptides were conjugated to polylysine and subsequently injected into rabbits to raise the antibodies. The anti-Tiam1-specific antibody was collected from each bleed and stored at 4°C containing 0.1% azide. The anti-Tiam1 IgG fraction was prepared by conventional DEAE-cellulose chromatography, respectively. Mouse monoclonal anti-HA (hemagglutinin epitope) antibody (clone 12 CA5) and mouse monoclonal anti-green fluorescent protein (GFP) antibody were purchased from Boehringer Mannheim and PharMingen, respectively. *Escherichia coli* (*E. coli*)-derived GST-tagged Rac1/Cdc42 and GST-tagged RhoA was kindly provided by Dr. Richard A. Cerione (Cornell

University, Ithaca, NY) and Martin Dr. Martin Schwartz (Scripps Research Institute, La Jolla, CA), respectively. Mouse monoclonal erythrocyte ankyrin (ANK1) antibody was prepared as described previously (Bourguignon, et al., 1993a). Rabbit anti-ANK3 antibody was kindly provided by Dr. L. L. Peters (Jackson Laboratory, Bar Harbor, ME) (Peters, et al., 1995).

Cloning, Expression and Purification of GST-tagged Ankyrin Repeat Domain (GST-ARD) and GFP-tagged Spectrin Binding Domain (GFP-SBD) of Ankyrin: pGEX-2TK recombinant plasmid expressing GST-ARD (N-terminal portion of ankyrin, residues 1-834) was constructed as follows. Two pGEX-2TK recombinant plasmids pA3-79 (expressing epithelial Ank3 N-terminal 1-455 amino acids) and pA3-88 (expressing epithelial Ank3 N-terminal 317-834 amino acids) (Peters, et al., 1995) were kindly provided by Dr. L. L. Peters from Jackson Laboratory. The two plasmids were digested by EcoRI (one of pGEX-2TK vector cloning sites) and NheI (in ankyrin cDNA 1176 bp) sequentially. The digested products were run in 1% agarose gel and purified with Qiagen purification kit (Qiagen Inc., Chatsworth, CA). The larger cDNA fragment in pA3-79 digested products (containing the pGEX-2TK vector and ankyrin cDNA 1-1176 bp) and the smaller one in pA3-88 digested products (containing ankyrin cDNA 1176-2556 bp) were cut and purified. Then these two cDNA fragments were ligated and transformed to INV α F' competent cells. The obtained clones were sequenced to verify the correct generation of the full length ankyrin repeat domain (ARD).

Spectrin binding domain (SBD) cDNA of human erythrocyte ankyrin was cloned into the eukaryotic expression vector, GFPN1 (Clontech) using the PCR-based cloning strategy. Ankyrin's spectrin binding domain cDNA was amplified by PCR with two specific primers (left, 5'-CGCTCGAGATGAAGGCTGAGAGGCGGGATTCC and right, 5'-ATAAGCTTCAGGGGCGTCGGGGTCCTTCT) linked with specific enzyme digestion site (Xho I and Hind III). PCR product digested with Xho I and Hind III was purified with QIAquick PCR purification kit (Qiagen). Ankyrin's spectrin binding domain cDNA fragment was then cloned into GFPN1 vector digested with Xho I and Hind III. The cDNA sequence was confirmed by nucleotide sequencing analysis. The GFP tagged spectrin binding domain (SBD) of ankyrin is expressed as a 89kDa polypeptide in SP1 or COS-7 cells by SDS-PAGE and immunoblot analyses. The 89kDa GFP-SBD (but not ARD) displays specific spectrin binding property as described previously (Platt, et al. 1993). Subsequently, GFP-SBD was isolated from anti-GFP conjugated affinity columns and used in various *in vitro* binding experiments as described below.

Expression Constructs: Both the full-length mouse Tiam1 cDNA (FL1591) and the NH₂-terminally truncated Tiam1 cDNA (C1199) were kindly provided by Dr. John G. Collard (The Netherlands Cancer Institute, The Netherlands). Specifically, the full-length Tiam1 (FL1591) cDNA was cloned into the eukaryotic expression vectors, pMT2SM. The truncated C1199 Tiam1 cDNA [carrying a hemagglutinin epitope (HA)-tag at the 3' end] was cloned in the eukaryotic expression vector, pUTSV1 (Eurogentec, Belgium).

The deletion construct, HA-tagged C1199 Tiam1 Δ 717-727 (deleting the sequence between aa717 and aa727 of Tiam1) was derived from C1199 Tiam1 using QuickChangeTM Site-Directed Mutagenesis Kit (Stratagene). Briefly, two complimentary mutagenic oligonucleotide primers containing the desired deletion (5'CCCAACCATCAACCAGGTGTTTGAGGGAATATTTGATG-3') was designed and synthesized. First, the cycling reaction utilizing 30ng double-stranded DNA template of C1199 Tiam1 plasmid and two complimentary primers was performed to produce mutated cDNA according to the manufacturer's instruction. Subsequently, 1 ul of the Dpn I restriction enzyme (10U/ul) was added directly to the cycling reaction products in order to digest

the parental supercoiled double-stranded DNA. This Dpn I -treated cDNA was used to transform supercompetent cells (e.g. Epicurian Coli XL 1-Blue). Finally the deletion construct was confirmed by DNA sequencing.

The Tiam1 (aa393-aa728) fragment was cloned into Calmodulin-Binding-Peptide (CBP)-tagged vector (pCAL-n)(Stratagen) using the PCR-based cloning strategy. Using human Tiam1 cDNA as a template, the Tiam1 fragment was amplified by PCR with two specific primers (left, 5'-AACTCGAGATGAGTACCAACAGTGAG-3' and right, 5'-AAAAAGCTTTCAGCCATCTGGAACAGTGTATC-3') linked with specific enzyme digestion site (XhoI or Hind III). PCR product digested with Xho I and Hind III was purified with QIAquick PCR Purification Kit(Qiagen). The Tiam1 fragment cDNA was cloned into pCAL-n vector digested with Xho I and Hind III. The inserted Tiam1 fragment sequence was confirmed by nucleotide sequencing analyses. The recombinant plasmids were transformed to BL21-DE3 to produce CBP-tagged Tiam1 fragment fusion protein. This fusion protein was purified from bacteria lysate by calmodulin affinity resin column (Sigma).

The Tiam1 fragment cDNA was also cloned into pEGFPN1 vector (Clontech) digested with Xho I and Hind III to create GFP-tagged Tiam1 fragment cDNA. The inserted Tiam1 fragment sequence was confirmed by nucleotide sequencing analyses. This GFP-tagged Tiam1 fragment cDNA was then used for transient expression in SP1 cells as described below. The GFP tagged Tiam1 fragment is expressed as a 68kDa polypeptide in SP1 or COS-7 cells by SDS-PAGE and immunoblot analyses.

Cell Transfection: To establish a transient expression system, cells (e.g. SP-1 cells or COS-7 cells) were transfected with various plasmid DNAs including Tiam1 cDNAs [e.g. the full-length mouse Tiam1 cDNA (FL1591) or HA-tagged C1199 Tiam1 cDNA or HA-tagged C1199 Tiam1 Δ 717-727 cDNA or GFP-tagged Tiam1 fragment cDNA or HA-tagged C1199 Tiam1 cDNA plus GFP-tagged Tiam1 fragment cDNA (co-transfection) or vector control constructs] using electroporation methods. Briefly, cells (e.g. SP-1 cells or COS-7 cells) were plated at a density of 1×10^6 cells per 100 mm dish and were transfected with 25 μ g/dish plasmid DNA using electroporation at 230v and 960 μ FD with a Gene Pulser (Bio-Rad). Transfected cells were grown in 5% or 20% fetal calf serum-containing culture medium for at least 24-48h. Various transfectants were then analyzed for the expression of Tiam1 or HA-tagged (or GFP-tagged) Tiam1 mutant proteins by immunoblot, immunoprecipitation and functional assays as described below.

Immunoprecipitation and Immunoblotting Techniques: SP-1 cells or COS cells [e.g. untransfected or transfected by various Tiam1 cDNAs including the full-length mouse Tiam1 cDNA (FL1591) or HA-tagged C1199 Tiam1 cDNA or HA-tagged C1199 Tiam1 Δ 717-727 cDNA] were first extracted with a solution containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, and 1% Nonidet P-40 (NP-40) buffer followed by solubilizing in SDS sample buffer and analyzed by SDS-PAGE (with 7.5% gel). Separated polypeptides were then transferred onto nitrocellulose filters. After blocking non-specific sites with 3% bovine serum albumin, the nitrocellulose filters were incubated with rabbit anti-Tiam1 (5 μ g/ml) or mouse anti-HA ((5 μ g/ml) [or preimmune serum (5 μ g/ml)] plus peroxidase-conjugated goat anti-rabbit IgG or goat anti-mouse IgG (1:10,000 dilution), respectively. In controls, peroxidase-conjugated normal mouse IgG or preimmune rabbit IgG was also incubated with anti-Tiam1-mediated immuno-complex. The blots were developed using ECL chemiluminescence reagent (Amersham Life Science, England) according to the manufacturer's instructions.

In some cases, SP-1 cells [transfected with HA-tagged C1199 Tiam1cDNA or GFP-tagged Tiam1 fragment cDNA or co-transfected with HA-tagged C1199 Tiam1cDNA and GFP-tagged Tiam1 fragment cDNA] were immunoblotted with anti-HA antibody (5µg/ml) and anti-GFP antibody (5µg/ml), respectively followed by incubation with horseradish peroxidase-conjugated goat anti-mouse IgG (1:10,000 dilution) at room temperature for 1 h.

In some experiments, SP-1 cells or COS cells [e.g. untransfected or transfected by various Tiam1 cDNAs including the full-length mouse Tiam1cDNA (FL1591) or HA-tagged C1199 Tiam1cDNA or GFP-tagged Tiam1 fragment cDNA or HA-tagged C1199 Tiam1cDNA plus GFP-tagged Tiam1 fragment cDNA (co-transfection)] were immunoprecipitated with rabbit anti-Tiam1 (5µg/ml) or anti-ankyrin antibodies [e.g. rabbit anti-ANK3 antibody (5µg/ml) or mouse anti-ANK1 antibody (5µg/ml)] followed by immunoblotting/reblotting with ankyrin antibodies [e.g. rabbit anti-ANK3 antibody (1µg/ml) or mouse anti-ANK1 antibody (5µg/ml)] or rabbit anti-Tiam1 (1µg/ml), respectively followed by incubation with horseradish peroxidase-conjugated goat anti-rabbit IgG or goat anti-mouse IgG (1:10,000 dilution) at room temperature for 1 h. The blots were developed using ECL chemiluminescence reagent (Amersham Life Science, England) according to the manufacturers instructions.

Effects of Synthetic Peptides on Ankyrin-Tiam1 Interaction : Nitrocellulose discs (1 cm diameter) were coated with $\approx 1 \mu\text{g}$ of a panel of synthetic peptides including the ankyrin-binding region peptide ($^{717}\text{GEGTDAVKRS}^{727}\text{L}$), a scrambled peptide (GRATLEGSDKV) and another Tiam1-related peptide ($^{399}\text{GTIKRAPFLG}^{409}\text{P}$) (synthesized by Dr. Eric Smith, University of Miami). Following coating, the unoccupied sites on the discs were blocked by incubation with a solution containing 20 mM Tris-HCl (pH 7.4) and 0.3% bovine serum albumin at 4°C for 2 h. The discs were then incubated with various concentration of ^{125}I -labeled cytoskeletal proteins (erythrocyte ankyrin/ARD/ankyrin's SBD/spectrin) ($\approx 3000 \text{ cpm/ng}$) at 4°C for 2 h in 1 ml binding buffer (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.2 % bovine serum albumin).

In some experiments, ^{125}I -labeled Tiam1 ($\approx 3000 \text{ cpm/ng}$) was incubated with ankyrin-coated beads in the presence of various concentrations (10^{-10}M - 10^{-6}M) of unlabeled synthetic peptide (e.g. $^{717}\text{GEGTDAVKRS}^{727}\text{L}$ or the scrambled sequence, GRATLEGSDKV or another Tiam1-related peptide, $^{399}\text{GTIKRAPFLG}^{409}\text{P}$) at 4°C for 2 h in 1 ml binding buffer (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.2 % bovine serum albumin). In some experiments, ^{125}I -labeled Tiam1 fragment ($\approx 3000 \text{ cpm/ng}$) was also incubated with beads containing various cytoskeletal proteins such as intact ankyrin, ARD or spectrin binding domain of ankyrin (GFP-SBD) or GFP alone. Following binding, the peptide-coated discs (or cytoskeletal protein-conjugated beads) were washed three times in the binding buffer and the radioactivity associated with peptide-coated discs (or cytoskeletal protein-conjugated beads) was estimated. As a control, the ligands were also incubated with uncoated nitrocellulose discs (or beads) to determine the binding observed due to the "stickyness" of various ligands. Nonspecific binding was observed in these controls. In the peptide competition assay, the specific binding observed in the absence of any of the competing peptides is designated as 100%. The results represent an average of duplicate determinations for each concentration of the competing peptide used.

Binding of Ankyrin or ARD To Tiam1 *In Vitro*: Aliquots (0.5-1.0 µg protein) of purified Tiam1 [e.g. intact Tiam1 or C1199 Tiam1 or Tiam1 fragment] conjugated beads were incubated in 0.5 ml of binding buffer [20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.1% bovine serum albumin and 0.05% Triton X-100] containing various concentrations (10-800 ng/ml) of ^{125}I -labeled intact ankyrin (purified from human erythrocytes) (5,000 cpm/ng protein) or ^{125}I -labeled recombinant ARD

fragment at 4°C for 4 h. Specifically, equilibrium binding conditions were determined by performing a time course (1-10h) of ¹²⁵I-labeled ankyrin (or ARD) binding to Tiam1 at 4°C. The binding equilibrium was found to be established when the in vitro ankyrin (or ARD)-Tiam1 binding assay was conducted at 4°C after 4 h. Following binding, beads were washed extensively in binding buffer and the beads-bound radioactivity was counted.

As a control, ¹²⁵I-labeled ankyrin or ¹²⁵I-labeled ARD was also incubated with uncoated beads to determine the binding observed due to the non-specific binding of various ligands. Non-specific binding which represented approximately 20% of the total binding, was always subtracted from the total binding. Our binding data are highly reproducible. The values expressed in the result section represent an average of triplicate determinations of 3-5 experiments with a standard deviation less than ±5%.

In some cases, ¹²⁵I-ankyrin (1-10ng) was incubated with a polyacrylamide gel containing purified Tiam1 (obtained from anti-Tiam1 affinity column chromatography) in the absence or the presence of 100-fold excess amount of unlabeled ankyrin/spectrin (in the same binding buffer as described above) for 1h at room temperature. Following incubation, the gel was washed five times with the same binding solution and analyzed by autoradiographic analyses.

An in vitro binding assay designed to measure the stoichiometry of GST-ARD fusion protein and C1199Tiam1 was also carried out. Specifically, in each reaction, 15-60 µl of glutathione-Sepharose bead slurry containing GST-ARD or GST alone was suspended in 0.5 ml of binding buffer [20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.1% bovine serum albumin and 0.05% Triton X-100]. Purified C1199 Tiam1 (0.5µg-1.0µg) was then added to the bead suspension in the absence or the presence of an excess amount of CBP-tagged Tiam1 fragment (100µg) at 4°C for 4 h. Following binding, the GST fusion protein was eluted with its associated C1199 Tiam1 using 150µl of 50mM Tris-HCl (pH 8.0) buffer containing 30mM glutathione. The amount of eluted GST fusion protein and C1199 Tiam1 was then determined by SDS-PAGE and Coomassie blue staining followed by densitometric scanning using a software NIH Image V1.54. The amount of ARD (mol) per C1199Tiam1 (mol) was then calculated. Values represent relative binding abilities averaged from three experiments ±SEM.

Binding Of ¹²⁵I-Labeled Ankyrin To Tiam1 and Tiam1 Mutant Proteins: Both purified wild type (the full length Tiam1) and mutant proteins (e.g. HA-tagged C1199 Tiam1 or HA-tagged C1199 Tiam1Δ717-727) were bound to the anti-Tiam1 or anti-HA immunoaffinity beads, respectively. CBP-tagged Tiam1 fragment was also bound to Sepharose beads conjugated with calmodulin. Subsequently, aliquots (10-20 ng proteins) of these beads were incubated with 0.5 ml of a binding buffer (20 mM Tris.HCl pH 7.4, 150 mM NaCl, 0.1% bovine serum albumin and 0.05% Triton X-100) in presence of various concentrations (10-400 ng/ml) of ¹²⁵I-labeled ankyrin (5,000 cpm/ng protein) at 4°C for 5 h. Following binding, beads were washed extensively in binding buffer and the bead-bound radioactivity was counted.

As a control, ¹²⁵I-labeled ankyrin was also incubated with uncoated beads or preimmune IgG-coated beads to determine the binding observed due to the non-specific binding of the ligand. Non-specific binding which represented approximately 15-20% of the total binding, was always subtracted from the total binding. The values expressed in the result section represent an average of triplicate determinations of 3-5 experiments with a standard deviation less than ±5%.

Tiam1-Mediated GDP/GTP Exchange For RhoGTPases: Purified E. coli-derived GST-tagged GTPases (e.g. Rac1, Cdc42 or RhoA) (20pmole) were preloaded with GDP (30 μ M) in 10 μ l buffer containing 25mM Tris-HCl (pH 8.0), 1mM DTT, 4.7mM EDTA, 0.16mM MgCl₂ and 200 μ g/ml BSA at 37° for 7min. In order to terminate preloading procedures, additional MgCl₂ was then added to the solution (reaching a final concentration of 9.16mM) as described previously (Zhang, et. al., 1995). Tiam1 was then isolated from COS-7 cells (transfected with either the full-length Tiam1 cDNA or HA-tagged C1199Tiam1 cDNA) or SP1 cells [transfected with various plasmid DNAs such as HA-tagged C1199 Tiam1 cDNA, GFP-tagged Tiam1 fragment cDNA or HA-tagged C1199Tiam1 cDNA plus GFP-tagged Tiam1 fragment cDNA (as co-transfection) or vector alone] using anti-Tiam1 (or anti-HA or anti-GFP)-conjugated beads. In some cases, ankyrin-associated Tiam1 was isolated from SP1 cells [transfected with HA-tagged C1199 Tiam1 cDNA, GFP-tagged Tiam1 fragment cDNA or HA-tagged C1199Tiam1 cDNA plus GFP-tagged Tiam1 fragment cDNA (as co-transfection) or vector alone] using anti-ankyrin-conjugated beads.

Subsequently, 2pmole of Tiam1 [isolated from untransfected or transfected cells according to the procedures described above] was preincubated with no ankyrin or ankyrin [e.g. intact ankyrin or ARD (1 μ g/ml)] followed by adding to the reaction buffer containing 20mM Tris-HCl (pH 8.0), 100mM NaCl, 10mM MgCl₂, 100 μ M AMP-PNP, 0.5 mg/ml bovine serum albumin, and 2.5 μ M GTP γ ³⁵S (\approx 1,250Ci/mmol). Subsequently, 2.5pmole GDP-loaded GST-tagged RhoGTPases (e.g. Rac1, Rac1 or Cdc42) or GDP-treated GST were mixed with the reaction buffer containing Tiam1 and GTP γ ³⁵S to initiate the exchange reaction at room temperature. At various time points, the reaction of each sample was terminated by adding ice-cold termination buffer containing 20mM Tris-HCl (pH 8.0), 100mM NaCl, and 10 mM MgCl₂ as described previously (Michiels et al., 1995; Zhang, et al., 1995). The termination reactions were then filtered immediately through nitrocellulose filters, followed by one wash with the termination buffer. The filters were dissolved completely in scintillation fluid, and the radioactivity associated with the filters were measured by scintillation fluid. The amount of GTP γ ³⁵S bound to Tiam1 or control sample (preimmune serum-conjugated Sepharose beads) in the absence of RhoGTPases (e.g. Rac1, Cdc42 or RhoA) was subtracted from the original values. Data represent an average of triplicates from 3-5 experiments. The standard deviation was less than 5%.

Double Immunofluorescence Staining: SP1 cells [untransfected or transfected with various plasmid DNAs such as HA-tagged C1199 Tiam1 cDNA, GFP-tagged Tiam1 fragment cDNA or HA-tagged C1199Tiam1 cDNA plus GFP-tagged Tiam1 fragment cDNA (as co-transfection) or vector alone] were first washed with PBS [0.1M phosphate buffer (pH 7.5) and 150mM NaCl] buffer and fixed by 2% paraformaldehyde. Subsequently, cells were rendered permeable by ethanol treatment followed by staining with different immuno-reagents. Specifically, untransfected cells were incubated with Rhodamine (Rh)-conjugated rabbit anti-ANK3 (50 μ g/ml) and fluorescein (FITC)-conjugated anti-Tiam1 (50 μ g/ml), respectively. HA-tagged C1199 cDNA transfected cells were stained with Rh-conjugated rabbit anti-ANK3 antibody (50 μ g/ml) and FITC-conjugated mouse anti-HA IgG (50 μ g/ml), respectively. GFP-tagged Tiam1 fragment cDNA transfected cells were labeled with Rh-conjugated anti-ANK3 (50 μ g/ml). Some SP1 transfectants [co-transfected with Tiam1 fragment cDNA and HA-tagged C1199Tiam1 cDNA] were stained with Rh-conjugated anti-HA (50 μ g/ml) or Rh-conjugated anti-ANK3 (50 μ g/ml), respectively. To detect non-specific antibody binding, vector-transfected cells were labeled with Rh-conjugated anti-ANK3 (50 μ g/ml) followed by incubating with FITC-conjugated anti-HA (50 μ g/ml). No anti-HA labeling was observed in such control samples. In some experiments, GFP-tagged Tiam1 fragment cDNA transfected cells were also incubated with

Rh-labeled rabbit preimmune IgG (50 μ g/ml). No non-specific rhodamine staining was detected in these samples. The fluorescein- and rhodamine-labeled samples were examined with a confocal laser scanning microscope (MultiProbe 2001 Inverted CLSM system, Molecular Dynamics, Sunnyvale, CA).

Tumor Cell Migration and Invasion Assays: Twenty-four transwell units were used for monitoring *in vitro* cell migration and invasion as described previously (Bourguignon et al., 1998b; Bourguignon, et al., 2000; Merzak et al., 1994). Specifically, the 5 μ m porosity polycarbonate filters coated with the reconstituted basement membrane substance Matrigel (Collaborative Research, Lexington, MA) were used for the cell invasion assay (Bourguignon et al., 1998b; Merzak et al., 1994). The 5 μ m porosity polycarbonate filters (without Matrigel coating) were used for the cell migration assay (Bourguignon, et al., 2000; Bourguignon et al., 1998b; Merzak et al., 1994). SP-1 cells transfected with various Tiam1-related cDNAs [e.g. full-length Tiam1 cDNA or HA-tagged C1199Tiam1 cDNA or GFP-tagged Tiam1 fragment cDNA or HA-tagged C1199Tiam1 cDNA plus GFP-tagged Tiam1 fragment cDNA (co-transfection) or vector alone] [$\approx 1 \times 10^4$ cells/well in phosphate buffered saline (PBS), pH 7.2] [untreated or treated with cytochalasin D (20 μ g/ml) or DMSO alone] were placed in the upper chamber of the transwell unit. The growth medium containing high glucose DMEM supplemented by 10% fetal bovine serum were placed in the lower chamber of the transwell unit. After 18h incubation at 37°C in a humidified 95% air/5% CO₂ atmosphere, cells on the upper side of the filter were removed by wiping with a cotton swap. Cell migration and invasion processes were determined by measuring the cells that migrate to the lower side of the polycarbonate filters by standard cell number counting methods as described previously (Zhu and Bourguignon, 2000; Merzak et al., 1994). Each assay was set up in triplicate and repeated at least 5 times. All data was analyzed statistically by Student's t test and statistical significance was set at $p < 0.01$.

RESULTS

(A) Identification of The Guanine Nucleotide Exchange Factor, Tiam1 In Breast Tumor Cells (e.g. SP-1 Cells)

RhoGTPases such as Rac1 become activated when bound GDP is exchanged for GTP by a process catalysed by guanine nucleotide (GDP/GTP) exchange factors (GEFs) such as Tiam1 (T-lymphoma invasion and metastasis 1) (Habets et al., 1994). A Tiam1 transcript has previously been detected in breast cancer cells (Habets et al., 1995). In this study we have analyzed Tiam1 expression (at the protein level) in SP-1 breast tumor cells. Immunoblot analysis, utilizing anti-Tiam1 antibody designed to recognize the specific epitope located at the C-terminus of Tiam1 molecule, reveals a single polypeptide (M. W. \approx 200kDa) (Fig. 1, lane 1). This 200kDa Tiam1-like molecule expressed in SP-1 cells is very similar to the Tiam1 detected in COS-7 cells which were transiently transfected with the full-length Tiam1 cDNA (Fig. 1, lane 2) or N-terminally truncated C1199 Tiam1 cDNA [Fig. 1, lane 3-revealing primarily C1199Taim1 (160kDa) and a low level of endogeneous Tiam1 (200kDa)]. We believe that Tiam1 detected in SP-1 cells or COS-7 transfectants revealed by anti-Tiam1-mediated immunoblot is specific since no protein is detected in these cells using preimmune rabbit IgG (Fig. 1, lane 4-6).

To confirm that the Tiam1-like molecule functions as a GDP/GTP exchange factor [or a GDP-dissociation stimulator (GDS) protein] for Rac1, we have isolated Tiam1 from SP-1 cells using anti-Tiam1-conjugated Sepharose beads. Our results indicate that SP1's Tiam1 activates GDP/GTP exchange on GST-Rac1 (Fig. 2A-a) and, to a lesser extent, on GST-Cdc42 (Fig. 2A-b)

and GST-RhoA (Fig. 2A-c). The initial onset of the exchange reaction on GST-Rac1 occurs within 1/2-1 min after the addition of Tiam1 and the reaction reaches its maximal level approximately 16 min after Tiam1 addition (Fig. 2A-a). In contrast, the initial rate of Tiam1-catalyzed GDP/GTP exchange on Cdc42 (Fig. 2A-b) and RhoA (Fig. 2A-c) appears to be significantly lower than that detected on Rac1 (Fig. 2A-a). In control samples, the amount of [³⁵S]GTPγS associated with GST alone is found to be significantly decreased (Fig. 2A-d). Further analysis indicates that the ability of Tiam1 isolated from SP-1 cells to promote GDP/GTP exchange on Rac1 (Fig. 2B-a) is identical to that carried out by Tiam1 isolated from COS-7 transfected with the full-length Tiam1 cDNA (Fig. 2B-b) or N-terminally truncated C1199 Tiam1 cDNA (Fig. 2B-c). Therefore, we believe that Tiam1 in SP-1 cells clearly functions as a GDP/GTP exchange factor for Rho-like GTPases such as Rac1GTPase.

We have also noticed that Tiam1 isolated from non-transfected COS 7 cells grown in the presence of 20% fetal calf serum is capable of catalyzing GDP/GTP exchange on Rac1 at a much higher level (Fig. 2B-d-blank bar) than Tiam1 isolated from non-transfected COS 7 cells grown in the presence of 5% fetal calf serum (Fig. 2B-d-shaded bar). This observation is consistent with previous findings that some serum components play an important role in up-regulating the ability of Tiam1 to promote GDP/GTP exchange on Rac1 (Stam et al., 1998). In SP1 cells (Fig. 2B-a-blank and shaded bars) or Tiam1cDNA-transfected COS7 cells (Fig. 2B-b-blank and shaded bars; 2 B-c-blank and shaded bar), neither high nor low serum causes significant changes in the ability of Tiam1 to catalyze GDP/GTP exchange on Rac1. These differential serum effects on the activity of Tiam1 isolated from low or high Tiam1 expressing cells awaits future investigation.

(B) Interaction of Tiam 1 and the Cytoskeletal Proteins, Ankyrin

Certain cytoskeleton proteins, such as ankyrin, are known to be involved in regulating a variety of cellular activities (Bennett, 1992; Bennett and Gilligan, 1993; De Matteis and Morrow, 1998; Bourguignon, 1996; Bourguignon, et al., 1998a). Both ankyrin1 (ANK1) and ankyrin3 (ANK3) have been shown to be expressed in breast tumor cells (Bourguignon, et al., 1998b; Bourguignon, et al. 1999). In this study we have carried out anti-ANK1 or anti-ANK3-mediated immunoprecipitation of SP-1 cellular proteins followed by anti-Tiam1 immunoblot (Fig. 3A, lane 2; Fig. 3B, lane 2) and anti-ANK1 (Fig. 3A-lane 3)/ANK3 (Fig. 3B-lane 3) immunoblot, respectively. Our results indicate that the Tiam1 band is revealed in anti-ankyrin (e.g. ANK1 or ANK3)-mediated immunoprecipitated materials (Fig. 3A, lane 2; Fig. 3B, lane 2). Apparently, Tiam1 is co-precipitated with ANK1 and/or ANK3 (revealed by reblotting with anti-ANK1/ANK3 antibody) (Fig. 3A, lane 3; Fig. 3B, lane 3). In control samples, immunoblotting of anti-ANK1 or anti-ANK3-immunoprecipitated material using rabbit preimmune serum (Fig. 3A, lane 1; Fig. 3B, lane 1) does not reveal any protein associated with this material. Anti-Tiam1-mediated immunoprecipitation of SP-1 cellular proteins followed by anti-ANK1 (Fig. 3A, lane 4) or anti-ANK3 (Fig. 3B, lane 4)-mediated immunoblot also shows that both ANK1 (Fig. 3A, lane 4) and ANK3 (Fig. 3B, lane 4) can be co-precipitated with Tiam1 (revealed by reblotting with anti-Tiam1 antibody) (Fig. 3A, lane 5; Fig. 3B, lane 5). In controls, very little material is detected in this anti-Tiam1-mediated immuno-complex using either normal mouse IgG (Fig. 3A, lane 6; Fig. 3B, lane 6) or rabbit preimmune serum-mediated immunoblot (Fig. 3A, lane 7; Fig. 3B, lane 7). These findings clearly establish the fact that Tiam1 and ankyrin (e.g. ANK1 and ANK3) are closely associated with each other as a complex *in vivo* in breast tumor cells.

Further analyses utilizing an *in vitro* binding assay show that ¹²⁵I-labeled ankyrin [i.e. erythrocyte ankyrin (ANK1)] binds Tiam1 (isolated from SP1 cells) specifically (Fig. 4A-a). In addition, we have used ¹²⁵I-ankyrin to bind purified Tiam1 (isolated from SP-1 cells) on a gel (Fig.

4B-a). Our data indicate that Tiam1 binds to ankyrin (ANK1) (Fig. 4B-a) directly. In the presence of an excess amount of unlabeled ankyrin, the binding between ankyrin and Tiam1 is greatly reduced (Fig. 4A-b and 4B-b). Other cytoskeletal proteins, such as spectrin, do not interfere with ankyrin binding to Tiam1 (Fig. 4A-c and 4B-c). However, the precise functional domain(s) of ankyrin involved in Tiam1 binding remains to be determined.

The N-terminal region of ankyrin's membrane binding domain (Fig. 5A-a) is comprised of a tandem array of 24 ankyrin repeats (so-called ankyrin repeat domain, ARD) (Fig. 5A-b). The question of whether the membrane-binding domain of ankyrin (in particular, the ankyrin repeat domain, ARD) is involved in Tiam1 binding is now addressed in this study. First, the pGEX-2TK recombinant plasmid encoding ARD (N-terminal portion of ankyrin, from aa 1 to 834) was constructed with a GST tag and expressed in *E. coli* (Zhu and Bourguignon, 2000). The purified GST-tagged ARD fusion protein is expressed as a 116 kDa protein (Fig. 5B-lane 1). After the removal of GST tag by thrombin digestion, the ARD itself is found to be a 89 kDa polypeptide (Fig. 5B, lane 2), which is similar to the 89 kDa ankyrin repeat domain (ARD) obtained by enzymatic digestion of erythrocyte ankyrin (Davis and Bennett, 1990).

Next, we have used the ARD fragment of ANK3 (GST-ARD) and purified Tiam1 to identify the exact Tiam1 binding site(s) on the ankyrin molecule. Specifically, we have tested the binding of Tiam1 to ¹²⁵I-labeled intact erythrocyte ankyrin (ANK1) [or ¹²⁵I-labeled GST-ARD fragment of ANK3] under equilibrium binding conditions. Scatchard plot analyses indicate that intact erythrocyte ankyrin (ANK1) binds to Tiam1 at a single site (Fig. 5C) with high affinity [an apparent dissociation constant (K_d) of ≈ 0.72 nM]. This ankyrin-Tiam1 binding interaction is comparable in affinity to Tiam1 binding ($K_d \approx 1.42$ nM) to ANK3's ARD fragment (Fig. 5D). These findings strongly support the notion that ankyrin [in particular, the ankyrin repeat domain (ARD)] is involved in Tiam1 binding site.

(C) Determination of Tiam1's Ankyrin-Binding Domain

Previous studies indicate that Tiam1's NH2-terminal pleckstrin homology (PHn) domain and an adjacent protein interaction domain (i.e. a sequence between aa393-aa738 of Tiam1) (Fig. 6A-a,b,c) is required for the activation of Rac1 signaling pathways leading to membrane ruffling and C-Jun NH2-terminal kinase activation (Michiels, et al., 1997; Stam, et al., 1997). Using a 49kDa *E. coli*-derived calmodulin-binding peptide (CBP)-tagged Tiam1 fragment (i.e. aa393-aa738 of Tiam1) (Fig. 6B, lane 1) and an *in vitro* binding assay (Fig. 6C), we have detected a specific binding interaction between the Tiam1 fragment and ankyrin (Fig. 6C-a) and ARD (Fig. 6C-b) but not the spectrin binding domain of ankyrin (Fig. 6C-c) or spectrin (Fig. 6C-d).

Furthermore, we have evaluated the binding interaction between GST-ARD fusion protein and the recombinant C1199 Tiam1 (N-terminally truncated Tiam1) (Fig. 6D). First, glutathione-Sepharose beads containing GST-ARD were incubated with C1199 Tiam1 in the absence (Fig. 6D, lane 1; and Fig. 6E-lane 1) or the presence of an excess amount of Tiam1 fragment (Fig. 6D, lane 2; and Fig. 6E, lane 2). In controls, C1199 Tiam1 was also added to Sepharose beads containing GST alone (Fig. 6D, lane 3; and Fig. 6E, lane 3). Following binding, the GST fusion protein was eluted with its associated C1199 Tiam1 using a buffer containing glutathione. The amount of eluted GST fusion protein and C1199 Tiam1 was then determined by SDS-PAGE and Coomassie blue staining (Fig. 6E) followed by densitometric scanning analyses (Fig. 6D). Our results indicate that the stoichiometry of ARD:C1199 Tiam1 interaction is approximately 1:1 (Fig. 6D, lane 1; Fig. 6E, lane 1a and b). In the presence of an excess amount (≈ 100 -fold) of recombinant Tiam1 fragment, the binding between ankyrin ARD and C1199Tiam1 is significantly reduced (Fig. 6D-lane 2a and b; and

Fig. 6E-lane 2a and b). The control beads containing GST alone fail to bind C1199 Tiam1 (Fig. 6D, lane 3; and Fig. 6E, lane 3a and b). These observations suggest that (i) ankyrin ARD directly interacts with Tiam1; and (ii) the ankyrin-binding domain (ARD)-containing Tiam1 fragment act as a potent competitive inhibitor of Tiam1 binding to ankyrin *in vitro*.

Protein sequence analyses show that Tiam1 contains the sequence ⁷¹⁷GEGTDAVKRS⁷²⁷L" (in mouse), or ⁷¹⁷GEGTEAVKRS⁷²⁷L (in human) which shares a great deal of sequence homology with the ankyrin binding domain of the cell adhesion receptor, CD44 family (Lokeshwar, et al., 1994; Zhu and Bourguignon, 1998). To test whether the sequence "GEGTDAVKRSL" of Tiam 1 protein is in fact involved in ankyrin binding, we have examined the ability of an 11 amino acid synthetic peptide, identical to "GEGTDAVKRSL", to bind various cytoskeletal proteins. As shown in Table 1, this synthetic peptide binds specifically to intact ankyrin and the ankyrin-repeat domain (ARD), but not ankyrin's spectrin binding domain (SBD) or other cytoskeletal proteins such as spectrin. Control peptides, containing the scrambled sequence (GRATLEGSDKV) with the same amino acid composition as that of the synthetic peptide or another peptide (GTIKRAPFLGP) from different region (i.e. the sequence between aa399 and aa409) of Tiam1, fail to bind any cytoskeletal proteins tested (Table 1).

We have also used the synthetic peptide corresponding to Tiam1's aa717-aa727 sequence to compete for the binding of purified Tiam1 to ankyrin. As shown in Fig. 7A, the synthetic peptide competes effectively with Tiam1 to bind ankyrin with an apparent inhibition constant (K_i) \approx 0.5 nM (Fig. 7A-c). However, control peptides such as GRATLEGSDKV (Fig. 7A-a) or GTIKRAPFLGP (Fig. 7A-b) do not compete at all with Tiam1 in ankyrin binding. These result suggest that the aa717-aa727 sequence of Tiam1 is a critical part of the ankyrin binding domain of Tiam1. Finally, we have constructed an HA-tagged C1199 Tiam1 deletion mutant lacking the ankyrin binding sequence, aa717-aa727 (designated as C1199 Tiam1 Δ 717-727) (Fig. 7B-b). The truncated C1199 Tiam1 Δ 717-727 cDNA (Fig. 7B-b) and the wild-type C1199 Tiam1 (Fig. 7B-a) were then transiently transfected into SP-1 cells, respectively. Our results indicate that both the C1199 Tiam1 Δ 717-727 mutant (Fig. 7C, lane 3) and the wild-type C1199 Tiam1 (Fig. 7C-lane 2) are expressed as a 160 kDa polypeptide in SP-1 transfectants using anti-HA-mediated immunoblotting. No protein band was detected in vector-transfected SP-1 cells (Fig. 7C, lane 1). Further analyses using anti-HA-conjugated immunobeads indicate that the HA-tagged C1199 Tiam1 Δ 717-727 mutant protein isolated from SP-1 transfectants displays a drastic reduction (approximately \approx 90-95% inhibition) in ankyrin-binding ability (Fig. 7D-c) compared to the HA-tagged wild-type C1199 Tiam1 (Fig. 7D-b). No ankyrin binding is observed in materials associated with anti-HA-beads isolated from vector-transfected cells (Fig. 7D-a). These finding suggest that the aa717-aa727 region is critical for the interaction of Tiam1 with ankyrin.

Most importantly, we have found that the binding of ankyrin [e.g. erythrocyte ankyrin (ANK1) (Fig. 8A) or ANK3's ARD (Fig. 8B)] to Tiam1 significantly increases the GDP/GTP exchange activity of Rac1 GTPase as compared to untreated Tiam1-mediated Rac1 activation (Fig. 8C). The spectrin binding domain of ankyrin or other cytoskeletal proteins, such as spectrin, fail to stimulate Tiam1-mediated GDP/GTP exchange on Rac1 GTPase (data not shown). Therefore, we believe that ankyrin binding to Tiam 1 plays a pivotal role in the up-regulation of Tiam 1-mediated GDP-GTP exchange activity of Rho-like GTPases (e.g. Rac1).

(D) Effect of Tiam1 or the Tiam1 Fragment On Rac1 Activation, Tumor Cell Invasion and Migration

Previous studies have indicated that both ankyrin and Tiam1 are closely associated with certain tumor-specific behaviors, characterized by an "invadopodia" structure (or membranous projections) (Mueller and Chen, 1991; Monsky, et al., 1994) and epithelial tumor cell migration (Bourguignon et al., 1998a; 1998b; Zhu and Bourguignon, 2000; Bourguignon, et al., 2000). In this study using double immuno-labeling staining, we have observed that both ankyrin (Fig. 10A) and Tiam1 (Fig. 10B) are co-localized in the plasma membrane and long projections of SP1 cells (Fig. 10C). Furthermore, we have transiently transfected breast tumor cells (e.g. SP-1 cells) with HA-tagged N-terminally truncated C1199 Tiam1 cDNA. Our results show that the C1199 Tiam1 is expressed as a 160 kDa protein (Fig. 9B-a) detected by anti-HA-mediated immunoblot in SP1 cells. No protein band was detected in vector-transfected SP1 cells by anti-HA-mediated immunoblotting (Fig. 9A-a). Double immunofluorescence staining data show that ankyrin (Fig. 10D) and C1199Tiam1 (Fig. 10E) are also co-localized on the plasma membrane-related long projections of these C1199cDNA-transfected cells (Fig. 10F). Furthermore, we have demonstrated that transfection of SP1 cells with C1199 Tiam1 cDNA stimulates ankyrin-associated Tiam1-catalyzed GDP/GTP exchange on Rac1 (Fig. 11a), and induces a significant amount of increase in breast tumor cell invasion (Table 2A) and migration (Table 2B) as compared to vector-transfected SP1 transfectants (11b and Table 2A,B). These results are consistent with previous findings indicating that transfection of NIH3T3 cells with the N-terminally truncated C1199 Tiam1 cDNA confers potent oncogenic properties (Van Leeuwen, et al., 1995).

Treatment of SP1 cells (e.g. untransfected cells or transfected cells) with certain agents [e.g. cytochalasin D (a microfilament inhibitor)] causes a remarkable inhibition of tumor cell invasion (Table 2A) and migration (Table 2B). Tiam1-Rac1 signaling initiates oncogenic cascades including c-Jun Kinase (JNK) activation which triggers gene transcription through c-jun and promotes cell transformation (Michiels, et al., 1995; Michiels, et al., 1997). In addition, Tiam1-activated Rac1 stimulates the novel family of serine/threonine kinases, Paks (p-21 activated kinases) (Manser, et al., 1994; Knaus, et al., 1995; Bagrodia and Cerione, 1999) which mediate actin assembly and induce the formation of membrane ruffling and lamellipodia (membrane projections). In fact, cytoskeleton-associated membrane projections are often tightly linked to matrix degrading enzymes during breast tumor cell invasion and migration (Bourguignon, et al. 1998b). These findings suggest that Tiam1-Rac1 signaling and selective effector(s) play an important role in promoting certain gene expression required for cellular transformation and the up-regulation of cytoskeletal changes needed for tumor cell invasion and migration. Identification of immediate downstream targets for ankyrin-mediated Tiam1-Rac1 signaling is currently under investigation in our laboratory.

We have also found that SP1 cells transfected with GFP-tagged Tiam1 fragment cDNA express a 68 kDa protein as detected by anti-GFP antibody (Fig. 6B, lane 2; Fig. 9C-b). In vector-transfected SP1 cells, we are not able to detect any protein band by anti-GFP-mediated immunoblotting (Fig. 9A-b). Double immunofluorescence staining shows that both ankyrin (Fig. 10G) and the GFP-tagged Tiam1 fragment (Fig. 10H) are co-localized in the cell membranes in SP1 transfectants (Fig. 10I). We believe that ankyrin staining detected in these SP1 transfectants revealed by anti-ankyrin-mediated immuno-staining is specific since no label (Fig. 10a) is detected in these GFP-Tiam1 fragment overexpressed cells (Fig. 10b) using preimmune rabbit IgG (Fig. 10a). No co-localization (Fig. 10c) of preimmune IgG (Fig. 10a) and GFP-Tiam1 fragment (Fig. 10b) is observed in these transfectants. Moreover, we have demonstrated that overexpression of GFP-tagged Tiam1

fragment in SP1 transfectants downregulates ankyrin-associated Tiam1-Rac1 signaling (Fig. 10d) and tumor cell invasion (Table 2A) as well as cell migration (Table 2B).

Finally, co-transfection of SP1 cells with HA-tagged C1199 Tiam1 cDNA and GFP-tagged Tiam1 fragment cDNA was carried out. Using anti-HA or anti GFP-mediated immunoblotting technique, we have detected co-expression of both C1199 Tiam1 (Fig. 9D-a) and Tiam1 fragment (Fig. 9D-b) in SP1 transfectants. In control experiments, no detectable signal was observed when these transfectants were immunoblotted with anti-GFP (Fig. 9B-b) or anti-HA (Fig. 9C-a), respectively. Furthermore, immunocytochemical staining results show that ankyrin (Fig. 10d) and the GFP-tagged Tiam1 fragment (Fig. 10e) are co-localized (Fig. 10f) in the plasma membranes of SP1 transfectants. In contrast, C1199 Tiam1 (Fig. 10J) fails to display plasma membrane localization. Consequently, the amount of co-localization (Fig. 10L) between C1199 Tiam1 (Fig. 10J) and Tiam1 fragment (Fig. 10K) is greatly reduced. In addition, it is noted that no significant stimulation of long membrane projections was observed in these transfectants (Fig. 10 J,K,L; and 10 d,e,f). Other tumor-specific behaviors such as Tiam1-Rac1 activation (Fig. 11c) and cytoskeleton-mediated breast tumor cell invasion (Table 2A) and migration (Table 2B) are also greatly inhibited. These findings suggest that the ankyrin-binding domain containing Tiam1 fragment acts as a dominant-negative mutant which effectively competes for ankyrin binding to C1199Tiam1 *in vivo* and blocks ankyrin-regulated Tiam1 function associated with tumor-specific phenotypes.

KEY RESEARCH ACCOMPLISHMENTS:

- We have found that Tiam1 (T lymphoma invasion and metastasis) is one of the known guanine nucleotide (GDP/GTP) exchange factors (GEFs) for RhoGTPases (e.g. Rac1) and is expressed in breast tumor cells (e.g. SP-1 cell line).

(A)Tiam1 Interaction With the Cytoskeletal Protein, Ankyrin:

- Tiam1 and the cytoskeletal protein, ankyrin, are physically associated as a complex *in vivo*.
- The ankyrin repeat domain (ARD) of ankyrin is responsible for Tiam1 binding; the 11aa sequence between aa717 and aa727 of Tiam1 (⁷¹⁷GEGTDAVKRS⁷²⁷L) is the ankyrin binding domain.
- Most importantly, ankyrin binding to Tiam1 activates GDP/GTP exchange on RhoGTPases (e.g. Rac1).
- Using an Escherichia coli-derived calmodulin-binding peptide (CBP)-tagged recombinant Tiam1 (aa393-aa728) fragment which contains the ankyrin-binding domain, we have detected a specific binding interaction between the Tiam1 (aa393-aa738) fragment and ankyrin *in vitro*. This Tiam1 fragment also acts as a potent competitive inhibitor for Tiam1 binding to ankyrin.
- Transfection of SP-1 cell with Tiam1 cDNAs stimulates (i)Tiam1-ankyrin association in the membrane projections, (ii) Rac1 activation and (iii) breast tumor cell invasion and migration. Co-transfection of SP1 cells with green fluorescent protein (GFP)-tagged Tiam1 fragment cDNA and Tiam1 cDNA effectively blocks Tiam1-ankyrin co-localization in the cell membrane and inhibits GDP/GTP exchange on Rac1 by ankyrin-associated Tiam1 and tumor-specific phenotypes.

(B) Tiam1 Interaction With The Metastasis-Specific Molecule, CD44 [the hyaluronic acid (HA) binding receptor]:

- We have also explored the interaction between the metastasis-specific molecule, CD44 [the hyaluronic acid (HA) binding receptor] and Tiam1 (a guanine nucleotide exchange factor) in metastatic breast tumor cells (SP1 cell line).
- Scatchard plot analysis indicates that there is a single high affinity CD44 binding site in Tiam1's PHn-CC-Ex domain with an apparent dissociation constant (Kd) of 0.2nM which is comparable to CD44 binding (Kd \approx 0.13nM) to intact Tiam1. These findings suggest that the PHn-CC-Ex domain is the primary Tiam1 binding region for CD44.
- Most importantly, the binding of HA to CD44v3 of SP1 cells stimulates Tiam1-catalyzed Rac1 signaling and cytoskeleton-mediated tumor cell migration.
- Transfection of SP1 cells with Tiam1cDNA promotes Tiam1 association with CD44v3 and upregulates Rac1 signaling as well as HA/CD44v3-mediated breast tumor cell migration. Co-transfection of SP1 cells with PHn-CC-Ex cDNA and Tiam1 cDNA effectively inhibits Tiam1 association with CD44 and efficiently blocks tumor behaviors.
- These observations clearly suggest that Tiam1 contains multiple functional domains [e.g. membrane localization site(s) and cytoskeleton binding domains] required for the regulation of Tiam1-Rac1 signaling and cytoskeleton function leading to metastatic breast tumor cell progression.

REPORTABLE OUTCOMES:

- Manuscripts and abstracts: see section #13 (final report section).
- Funding applied for based on work supported by this award:

Funded Active Grants:

NCI Grant (2000-2005) "CD44/Variant-Cytoskeleton In Breast Cancer Progression".

NCI Grant (1999-2003) "CD44-p185^{HER2} Interaction In Ovarian Cancer Progression".

US Army Breast Cancer Grant (DOD) (1999-2002) "A Novel Signaling Perturbation and Ribozyme Gene Therapy Procedure to Block Rho-Kinase (ROK) Activation and Breast Tumor Metastasis".

CONCLUSIONS:

The invasive phenotype of breast tumors, determined by characteristics such as tumor cell motility and membrane perturbations, is clearly linked to cytoskeletal function. For example, recent studies have shown that certain metastasis-specific molecules [e.g. CD44_{v3,8-10} isoform (Bourguignon, et al., 1998b; Bourguignon, et al., 1999) and its associated matrix metalloproteinase, MMP-9 (Bourguignon, et al., 1998b; Yu and Stamenkovic, 1999), as well as Rho-Kinase (ROK) (Bourguignon, et al., 1999)] are closely associated with the cytoskeleton during tumor cell function. In order to further examine the regulatory mechanism(s) involved in cytoskeleton-mediated oncogenic signaling leading to tumor cell invasion and migration, we have focused on the guanine nucleotide exchange factors (GEFs-the Dbl or DH family) such as Tiam1 which are known to display oncogenic capability and function as upstream activators of Rho-like GTPases (e.g. Rac1 or Cdc42) (Habets et al., 1994; Michiels et al., 1995; Woods et al., 1991; van Leeuwen et al., 1995; Nobes and Hall, 1995). In breast tumor cells, such as SP-1 cells, Tiam1 is detected as a 200 kD protein (Fig. 1) that is similar to Tiam1 described in other cell types (Michiels et al., 1995; Woods et al., 1991; van Leeuwen et al., 1995; Nobes and Hall, 1995; Stam et al., 1997; Hordijk et al., 1997; van Leeuwen et al., 1997; Bourguignon, et al., 2000). Tiam1 isolated from SP-1 cells is also capable of carrying out GDP/GTP exchange for Rac1 *in vitro* (Fig. 2). Sequence analysis of Tiam1 suggests that its association with the invasive and metastatic phenotype is mediated via membrane-linked cytoskeletal regulation and/or activation of Rho family GTPases (Habets et al., 1994; Nobes and Hall, 1995).

Rac1 acts downstream of Tiam1 signaling and regulates the function of several cell adhesion molecules such as the laminin receptor, $\alpha 6 \beta 1$ integrin (van Leeuwen et al., 1997), E-cadherin (Hordijk et al., 1997) and the hyaluronan receptor, CD44 (Bourguignon, et al., 2000). Tiam1-Rac1 activation has also been shown to be stimulated by certain serum-derived growth activators [e.g. sphingosine-1-phosphate (S1P) and LPA] during T-lymphoma cell invasion (Stam et al., 1998). However, in epithelial Madin-Darby canine kidney (MDCK) cells, Tiam1-Rac1 signaling plays an invasion-suppressor role in Ras-transformed MDCK cells (Hordijk et al., 1997). Apparently, various responses by Tiam1-catalyzed Rac1 signaling may be controlled by selective upstream activators [e.g. availability of certain cytoskeletal proteins (e.g. ankyrin), cell adhesion receptors (e.g. CD44, integrin or E-cadherin), growth activators (e.g. serum, S1P or LPA) or extracellular matrix components (hyaluronic acid, collagen or fibronectin, etc.]. Moreover, Tiam1 is found to be involved in promoting both Rac1- and RhoA-mediated pathways during neurite formation in nerve cells (van Leeuwen et al., 1997). The balance between Rac1 and RhoA determines a particular cellular morphology and migratory behaviors (Sander, et al., 1999).

Ankyrin is a family of membrane-associated cytoskeletal proteins expressed in a variety of biological systems including epithelial cells and tissues (Peters and Lux, 1993). Presently, at least three ankyrin genes have been identified: ankyrin 1 (Ank 1 or ankyrin R), ankyrin 2 (Ank 2 or ankyrin B) and ankyrin 3 (Ank 3 or ankyrin G) (Lux et al., 1990; Otto, et al., 1991; Kordeli, et al., 1995; Peters, et al., 1995). These molecules belong to a family of related genes that probably arose by duplication and divergence of a common ancestral gene. Ankyrin is known to bind to a number of plasma membrane-associated proteins including band 3, two other members of the anion exchange gene family (Bennet, 1992), Na⁺/K⁺-ATPase (Nelson and Veshnock, 1987; Zhang, et al., 1998), the amiloride-sensitive Na⁺ channel (Smith et al., 1991), the voltage-dependent Na⁺ channel (Kordeli et al., 1995), Ca²⁺ channels (Bourguignon et al., 1993b; Bourguignon and Jin, 1995; Bourguignon et al., 1995a) and the adhesion molecule, CD44 (Bourguignon, et al., 1986; Kalomiris and Bourguignon, 1988; Kalomiris and Bourguignon, 1989; Lokeshwar and Bourguignon, 1991; Lokeshwar and

Bourguignon, 1992; Bourguignon, et al., 1992; Bourguignon, et al., 1991; Lokeshwar, et al., 1994; Lokeshwar, et al., 1996; Bourguignon, 1996). It has been suggested that the binding of ankyrin to certain membrane-associated molecules is necessary for signal transduction, cell adhesion, membrane transport, cell growth, migration and tumor metastasis (Bennet, 1992; Bourguignon et al., 1995b; Bourguignon, 1996; Bourguignon et al., 1997; Bourguignon et al., 1998a; De Matteis and Morrow, 1998; Zhu and Bourguignon, 1998; Zhu and Bourguignon, 2000).

In this study we have presented a new evidence showing the interaction between ankyrin and Tiam1. Specifically, we have demonstrated that Tiam1 and ankyrin (e.g. ANK1 and ANK3) are physically linked to each other as a complex *in vivo* (Figs. 3 and 10) and *in vitro* (Figs. 5,6 and 7); and that ankyrin binding to Tiam1 promotes Rac1 activation (Figs. 8 and 11). Using purified Tiam1 and GST-tagged ankyrin repeat domain (GST-ARD) (Fig. 5) to examine the interaction between Tiam1 and ankyrin *in vitro*, we have found that the ankyrin repeat domain (ARD) is directly involved in the binding of Tiam1 (Fig. 5 C and D; and Fig. 6 C, D and E). In fact, the binding affinity of ARD to Tiam1 is very comparable to that of intact erythrocyte ankyrin binding to Tiam1 (Fig. 5C and D). These findings support the conclusion that the ARD fragment of ankyrin is directly involved in the recognition of Tiam1. The 24 ankyrin repeats within the ARD are known to form binding sites for at least seven distinct membrane protein families (Michaely and Bennett, 1995). Often, the ARD is organized into four folding subdomains [e.g. subdomain1 (S1), subdomain 2 (S2), subdomain 3 (S3) and subdomain 4 (S4)]. Recently, we have shown that the subdomain 2 (S2) (but not other subdomains) of ARD binds to the adhesion molecule, CD44 directly (Zhu and Bourguignon, 2000). Overexpression of subdomain (S2) of ARD promotes CD44-mediated tumor cell migration (Zhu and Bourguignon, 2000). The question of which ARD subdomain fragment(s) is(are) involved in regulating Tiam1 function remains to be determined.

The structural homology between the ankyrin binding domain of Tiam1 (the sequence between aa717 and aa727) and CD44 is quite striking (Lokeshwar, et al. 1994). The cytoplasmic domain of CD44 (approximately 70 a. a. long) is highly conserved ($\geq 90\%$) in most of the CD44 isoforms; and it is clearly involved in specific ankyrin binding (Lokeshwar et al., 1994; Zhu and Bourguignon, 1998). The ankyrin-binding domain of CD44 has also been mapped using deletion mutation analyses and mammalian expression systems (Lokeshwar et al., 1994; Zhu and Bourguignon, 1998). In particular, the ankyrin-binding domain [e.g. "NGGNGTVEDRKPSSEL" between aa 306 and aa320 in the mouse CD44 (Lokeshwar et al., 1994) and "NSGNGAVEDRKPSGL" aa304 and aa318 in human CD44 (Zhu and Bourguignon, 1998)] is required for cell adhesion (Lokeshwar et al., 1994; Zhu and Bourguignon, 1998), the recruitment of Src kinase (Zhu and Bourguignon, 1998) and the onset of tumor cell transformation (Zhu and Bourguignon, 1998; Bourguignon, et al. 1998b). The facts that : (a) the recombinant C1199Tiam1 interacts with ARD fusion protein directly with a stoichiometry of 1:1 (Fig. 6D and E); (b) a peptide with the sequence ⁷¹⁷GEGTDAVKRS⁷²⁷L of Tiam1 binds to ankyrin and ARD but not ankyrin's spectrin binding domain or spectrin (Table 1); and (c) a Tiam1 peptide (aa717-aa727) competes with Tiam1 for the binding to ankyrin (Fig. 7A); (d) the Tiam1 deletion mutant protein (e.g. C1199 Tiam1 Δ 717-727) (Fig. 7B) fails to bind ankyrin (Fig. 7D); and (e) ankyrin stimulates Tiam1-catalyzed GDP/GTP exchange activity on Rac1 (Fig. 8) strongly suggest that the sequence (⁷¹⁷GEGTDAVKRS⁷²⁷L) of Tiam1 is an important region for ankyrin binding. Furthermore, we have shown that transfection of SP-1 cells with HA-tagged N-terminally truncated C1199 Tiam1 cDNA stimulates ankyrin-associated GDP/GTP exchange on Rac1 (Fig. 11) as well as tumor cell invasion (Table 2A) and migration (Table 2B). These Tiam1-activated oncogenic responses are consistent

with previous studies indicating Tiam1-activated Rho-like GTPases may act as downstream effectors of Ras in both tumorigenesis and progression to metastatic diseases (Habets et al., 1994; Habets et al., 1995; van Leeuwen et al., 1995).

The aa393-aa738 Tiam1 fragment (Fig. 6C) contains not only the putative ankyrin-binding domain (aa717-aa727) but also NH₂-terminal pleckstrin homology (PHn), the coiled coil region (CC) and an additional adjacent region (Ex) [also designated as PHn-CC-Ex domain] (Michiels et al., 1997). This Tiam1 fragment has been shown to be responsible for Tiam1's membrane localization, Rac1-dependent membrane ruffling and C-Jun NH₂-terminal kinase activation in fibroblasts and COS cells (Stam et al., 1997; Michiels et al., 1997). In this study we have found that co-transfection of SP1 cells with Tiam1 fragment cDNA and C1199 Tiam1cDNA effectively blocks tumor cell-specific behaviors [e.g. C1199 Tiam1 association with ankyrin in the cell membrane (Fig. 10), Rac1 activation (Fig. 11), tumor cell invasion (Table 2A) and migration (Table 2B)]. These findings further support our conclusion that the ankyrin-binding domain-containing Tiam1 fragment acts as a potent competitive inhibitor which is capable of interfering with C1199 Tiam1-ankyrin interaction *in vivo*. Recently, we have also demonstrated that the Tiam1 fragment is required for CD44 (the hyaluronan receptor) binding (Bourguignon, et al., 2000). Most importantly, Tiam1-CD44 interaction promotes Rac1 activation and hyaluronic acid-mediated breast tumor cell migration (Bourguignon, et al., 2000). These observations clearly suggest that the aa393-aa738 of Tiam1 contains multiple functional domains [e.g. membrane localization site(s) and cytoskeleton binding domains] required for the regulation of Tiam1-Rac1 signaling and cytoskeleton function. Taken together, we believe that ankyrin-Tiam1 interaction plays a pivotal role in regulating Rac1-activated oncogenic signaling and cytoskeleton-mediated metastatic breast tumor cell progression.

REFERENCES:

- Bagrodia, S. and R.A. Cerione. 1999. PAK to the future. *Trends in Cell Biol.* 9:350-355.
- Bennet, V. 1992. Ankyrins. *J. Biol. Chem.* 267:8703-8706.
- Bennet, V. and D. M. Gilligan 1993. The spectrin-based membrane skeleton and micro-scale organization of the plasma membrane. *Annu. Rev. Cell Biol.* 9:27-66.
- Bourguignon, L.Y.W., G. Walker, S. Suchard, and K. Balazovich. 1986. A lymphoma plasma membrane-associated protein with ankyrin-like properties. *J. Cell Biol.* 102:2115-2124.
- Bourguignon, L.Y.W., E. Kalomiris, and V.B. Lokeshwar. 1991. Acylation of the lymphoma transmembrane glycoprotein, GP85, may be required for GP85-ankyrin interaction. *J. Biol. Chem.* 266:11761-11765.
- Bourguignon, L.Y.W., V.B. Lokeshwar, J. He, X. Chen, and G. J. Bourguignon. 1992. A CD44-like endothelial cell transmembrane glycoprotein (GP116) interacts with extracellular matrix and ankyrin. *Mol. Cell. Biol.* 12:4464-4471.
- Bourguignon, L.Y.W., V.B. Lokeshwar, X. Chen, and W.G.L. Kerrick. 1993a. Hyaluronic acid-induced lymphocyte signal transduction and HA receptor (GP85/CD44)-cytoskeleton interaction. *J. Immunol.* 151:6634-6644.
- Bourguignon, L.Y.W., H. Jin, N. Iida, N. Brandt, and S.H. Zhang. 1993b. The involvement of ankyrin in the regulation of inositol 1,4,5-triphosphate receptor-mediated internal Ca²⁺ release from Ca²⁺ storage vesicles in mouse T-lymphoma cells. *J. Biol. Chem.* 268:7290-7297.
- Bourguignon, L.Y.W., and H. Jin. 1995. Identification of the ankyrin-binding domain of the mouse T-lymphoma cell inositol 1,4,5-triphosphate (IP₃) receptor and its role in the regulation of IP₃-mediated internal Ca²⁺ release. *J. Biol. Chem.* 270:7257-7260.

- Bourguignon, L.Y.W., A. Chu, H. Jin, and N.R. Brandt. 1995a. Ryanodine receptor-ankyrin interaction regulates internal Ca^{2+} release in mouse T-lymphoma cells. *J. Biol. Chem.* 270:17917-17922.
- Bourguignon, L.Y.W., N. Iida, C.F. Welsh, D. Zhu, A. Krongrad, and D. Pasquale. 1995b. Involvement of CD44 and its variant isoforms in membrane-cytoskeleton interaction, cell adhesion and tumor metastasis. *J. Neuro-Oncol.* 26:201-208.
- Bourguignon, L.Y.W. 1996. Interaction between membrane-cytoskeleton and CD44 during lymphocyte signal transduction and cell adhesion. *Current Topics in Membranes* (Ed: W.J. Nelson) 43:293-312.
- Bourguignon, L.Y.W., H. Zhu, A. Chu, N. Iida, L. Zhang, and H.C. Hung. 1997. Interaction between the adhesion receptor, CD44 and the oncogene product, p185^{HER2}, promotes human ovarian tumor cell activation. *J. Biol. Chem.* 272:27913-27918.
- Bourguignon, L.Y.W., D. Zhu, and H.B. Zhu. 1998a. CD44 isoform-cytoskeleton interaction in oncogenic signaling and tumor progression. *Frontiers in Bioscience* 3:637-649.
- Bourguignon, L.Y.W., Z. Gunja-Smith, N. Iida, H.B. Zhu, L.J.T. Young, W.J. Muller, and R.D. Cardiff. 1998b. CD44v_{3,8-10} is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells. *J. Cell. Physiol.* 176:206-215.
- Bourguignon, L.Y.W., H. B. Zhu, L. Shao, D. Zhu and Y.W. Chen. 1999. Rho-kinase (ROK) promotes CD44v_{3,8-10}-ankyrin interaction and tumor cell migration in metastatic breast cancer cells. *Cell Motility & Cytoskeleton*, 43:269-287.
- Bourguignon, L.Y.W., H. Zhu, L. Shao and Y.W. Chen. 2000. CD44 interaction with Tiam1 promotes Rac1 signaling and hyaluronic acid (HA)-mediated breast tumor cell migration. *J. Biol. Chem.* 275:1829-1838.
- Davis, L., and V. Bennett. 1990. Mapping the binding sites of human erythrocyte ankyrin of the anion exchanger and spectrin. *J. Biol. Chem.* 265:10589-10596.
- De Matteis, M.A. and J.S. Morrow. 1998. The role of ankyrin and spectrin in membrane transport and domain formation. *Current Opinion in Cell Biol.* 10:542-549.
- Dickson, R.B., and M.E. Lippman. 1995. The Molecular Basis of Cancer (Mendelsohn, J., Howlwy, P.M., and Israel, M.A. and Liotta, L.A., ed.), W.B. Saunders Company, Philadelphia, PA, pp. 358-359.
- Elliott, B.E., Maxwell, L., Arnold, M., Wei, W.Z. and Miller, E.R. 1988. Expression of epithelial-like markers and class-I major histocompatibility antigens by a murine carcinoma growing in the mammary gland and in metastasis: orthotopic site effects. *Cancer Res.* 48:7237-7245.
- Habets, G.G.M., E. H. M. Scholtes, D. Zuydgeest, R.A. van der Kammen, J.C. Stam, A. Berns, and J.G. Collard. 1994. Identification of an invasion-inducing gene, Tiam-1, that encodes a protein with homology to GDP-GTP exchangers for Rho-like proteins. *Cell* 77:537-549.
- Habets, G.G.M., R.A. van der Kammen, J.C. Stam, F. Michiels, and J. G. Collard. 1995. Sequence of the human invasion-inducing Tiam-1 gene, its conservation in evolution and its expression in tumor cell lines of different tissue origin. *Oncogene* 10:1371-1376.
- Hall, A. 1998. Rho GTPase and the actin cytoskeleton.. *Science* 279:509-514.
- Hart, M.J., A. Eva, T. Evans, S. A. Aaronson, and R. A. Cerione. 1991. Catalysis of guanine nucleotide exchange on the CDC42Hs protein by the dbl oncogene product. *Nature* 354:311-314.

- Hart, M.J., A. Eva, D. Zangrilli, S. A. Aaronson, T. Evans, R. A. Cerione, and Y. Zheng. 1994. Cellular transformation and guanine nucleotide exchange activity are catalyzed by a common domain on the *dbl* oncogene product. *J. Biol. Chem.* 269:62-65.
- Hordijk, P.L., J.P. ten Klooster, R.A. van der Kammen, F. Michiels, L.C. Oomen, and J.G. Collard. 1997. Inhibition of invasion of epithelial cells by Tiam1-Rac signaling. *Science* 278:1464-1466.
- Jiang, W. G., M. C. A. Puntis, and M. B. Hallett. 1994. Molecular and cellular basis of cancer invasion and metastasis: implications for treatment. *British J. Surgery* 81:1576-1590.
- Kalomiris, E.L., and L.Y.W. Bourguignon. 1988. Mouse T-lymphoma cells contain a transmembrane glycoprotein (GP85) which binds ankyrin. *J. Cell Biol.* 106:319-327.
- Kalomiris, E.L. and L.Y.W. Bourguignon. 1989. Lymphoma protein kinase C is associated with the transmembrane glycoprotein, GP85 and may function in GP85-ankyrin binding. *J. Biol. Chem.* 264:8113-8119.
- Knaus, U.G., S. Morris, H., Dong, J. Chernoff and G. M. Bokoch, 1995. Regulation of human leukocyte p21-activated kinases through G protein-coupled receptors. *Science* 269:221-223.
- Kordeli, E., S. Lambert, and V. Bennet. 1995. Ankyrin G, a new ankyrin gene with neural-specific isoforms localized at the axonal initial segment and node of Ranvier. *J. Biol. Chem.* 270:2352-2359.
- Lambert, S., H. Yu, J.T. Prchal, J. Lawler, P. Ruff, D. Speicher, D. and J. Palek. 1990. cDNA sequence for human erythrocyte ankyrin. *Proc. Natl. Acad. Sci. U.S.A.*, 87:1730-1734.
- Lauffenburger, D.A., and A.F. Horwitz.. 1996. Cell migration: A physically integrated molecular process. *Cell* 84:359-369.
- Lemmon, M.A., K. M. Ferguson, and J. Schlessinger. 1996. PH domains: diverse sequences with a common fold recruit signaling molecules to the cell surface. *Cell* 85:621-624.
- Lokeshwar, V.B. and L.Y.W. Bourguignon. 1991. Post-translational protein modification and expression of ankyrin-binding site(s) in GP85 (Pgp-1/CD44) and its biosynthetic precursors during T-lymphoma membrane biosynthesis. *J. Biol. Chem.* 266:17983-17989.
- Lokeshwar, V.B., N. Iida, and L.Y.W. Bourguignon. 1996. The cell adhesion molecule, GP116 is a new CD44 variant (ex14/v10) involved in hyaluronic acid binding and endothelial cell proliferation. *J. Biol. Chem.* 271:23853-13864.
- Lokeshwar, V.B. and L.W.B. Bourguignon. 1992. The lymphoma transmembrane glycoprotein GP85(CD44) is a novel guanine nucleotide-binding protein which regulates GP85(CD44)-ankyrin interaction. *J. Biol. Chem.* 267:22073-22078.
- Lokeshwar, V.B., N. Fregien, and L.Y.W. Bourguignon. 1994. Ankyrin-binding domain of CD44(GP85) is required for the expression of hyaluronic acid-mediated adhesion function. *J. Cell Biol.* 126:1099-1109.
- Lux, S.E., K. M. John and V. Bennett 1990. Analysis of cDNA for human erythrocyte ankyrin indicates a repeated structure with homology to tissue-differentiation and cell cycle control proteins. *Nature* 344:36-43.
- Manser, E., T. Leung, H. Salihuddin, Z. Zhao and L. Lim. 1994. A brain serine/threonine protein kinase activated by Cdc42 and Rac1. *Nature* 367:40-46.
- Merzak, A., S. Koochekpour, and G.J. Pilkington. 1994. CD44 mediates human glioma cell adhesion and invasion in vitro. *Cancer Res.* 54:3988-3992.
- Michaely, P., and V. Bennett, 1995. Mechanism for binding site diversity on ankyrin. *J. Biol. Chem.* 270:31298-31302.

- Michiels, F., J.C. Stam, P.L. Hordijk, R.A. van der Kammen, L. Ruuls-Van Stalle, C.A. Feltkamp, and J.G. Collard. 1997. Regulated membrane localization of Tiam1, mediated by the NH2-terminal pleckstrin homology domain, is required for Rac-dependent membrane ruffling and C-Jun NH2-terminal kinase activation. *J. Cell Biol.* 137:387-398.
- Michiels, F., G.G.M. Habets, J.C. Stan, R.A. van der Kammen, and J.G. Collard. 1995. A role for Rac in Tiam1-induced membrane ruffling and invasion. *Nature* 375:338-340.
- Monsky, W.L., C.Y. Lin, and W.T. Chen. 1994. A potential marker protease of invasiveness, is localized on invadopodia of human malignant melanoma cells. *Cancer. Res.* 54:5702-5710.
- Mueller, S.C. and W.T. Chen. 1991. Cellular invasion into matrix beads: localization of beta 1 integrins and fibronectin to the invadopodia. *J. Cell Sci.* 99:213-225.
- Nelson, W. J., and P.J. Veshnock. 1987. Ankyrin binding to Na⁺/K⁺-ATPase and implications for the organizations of membrane domains in polarized cells. *Nature (Lond).* 328:533-536.
- Nobes, C.D. and A. Hall. 1995. Rho, Rac and Cdc42 GTPases regulate the assembly of multi-molecular focal complexes associated with actin stress fibers, lamellipodia and filopodia. *Cell* 81:53-62.
- Otto, E., M. Kunitomo, T. McLaughlin and V. Bennett. 1991. Isolation and characterization of cDNA encoding human brain ankyrins reveal a family of alternatively spliced genes. *J. Cell Biol.* 114:241-253.
- Peters, L. L. and S.E. Lux. 1993 Ankyrins: structure and function in normal cells and hereditary spherocytes. *Semin. Hematol.* 30:85-118.
- Peters, L.L., K. M. John, F. M. Lu, E. M. Eicher, A. Higgins, M. Yialamas, L. C. Turtzo, A. J. Otsuka and S. E. Lux 1995. Ank3 (epithelial ankyrin), a widely distributed new member of the ankyrin gene family and the major ankyrin in kidney, is expressed in alternatively spliced forms, including forms that lack the repeat domain. *J. Cell Biol.* 130:313-330.
- Platt, O.S., S. E. Lux and J. F. Falcone. 1993. A highly conserved region of human erythrocyte ankyrin contains the capacity to bind spectrin. *J. Biol. Chem.* 268:24421-24426.
- Pontings, C.P. and C. Phillips. 1995. DHR domains in synthropins, neuronal NO synthases and other intracellular proteins. *Trends Biochem. Sci.* 20:102-103.
- Ridley, A.J. and A. Hall. 1992. The small GTP-binding protein Rho regulate the assembly of focal adhesion and actin fibers in response to growth factors. *Cell* 70:389-399.
- Sander, E.E., J.P. ten Klooster, S. van Delft, R.A. van der Kammen and J.G. Collard. 1999. Rac downregulates Rho activity: reciprocal balance between both GTPases determines cellular morphology and migratory behavior. *J. Cell Biol.* 147:1009-1022.
- Smith, P.R., G. Saccomani, E.H. Joe, K.J. Angelides, and D.J. Benos. 1991. Amiloride sensitive sodium channel is linked to the cytoskeleton in renal epithelial cells. *Proc. Natl. Acad. Sci. (USA)* 88:6971-6975.
- Stam, J.C., F. Michiels, R.A. van der Kammen, W.H. Moolenaar, and J.G. Collard. 1998. Invasion of T- lymphoma cells: cooperation between Rho family GTPases and lysophospholipid receptor signaling. *EMBO J.* 17:4066-4074.
- Stam, J.C., E.E. Sander, F. Michiels, F.N. van Leeuwen, H.E.T. Kain, R.A. van der Kammen, and J.G. Collard. 1997. Invasion of T-lymphoma cells: cooperation between Rho family GTPases and lysophospholipid receptor signaling. *J. Biol. Chem.* 272:28447-28454.
- Tse, W.T., J. C. Menninger, T.L. Yang-Feng, U. Francke, K.E. Sahr, and B. G. Forget. 1991. Isolation and chromosomal localization of a novel non-erythroid ankyrin gene. *Genomics*, 12:702-704.

- Yu, Q. and I. Stamenkovic. 1999. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. *Genes and Development* 13:35-48.
- Van Aelst, L., and C. D'Souza-Schorey. 1997. Rho GTPases and signaling networks. *Genes Dev.* 11:2295-2322.
- Van Leeuwen, F.N., R.A. van der Kammen, G.G.M. Habets, and J.G. Collard. 1995. Oncogenic activity of Tiam1 and Rac1 in NIH3T3 cells. *Oncogene* 11:2215-2221.
- Van Leeuwen, F.N., H.E. Kain, R.A. Kammen, F. Michiels, O.W. Kranenburg, and J.G. Collard. 1997. The guanine nucleotide exchange factor Tiam1 affects neuronal morphology; opposing roles for the small GTPases Rac and Rho. *J. Cell Biol.* 139:797-807.
- Woods, D.F. and P.J. Bryant. 1991. The discs-large tumor suppressor gene of *Drosophila* encodes a guanylate kinase homolog localized at septate junctions. *Cell* 66:451-464.
- Zhang, Y., Hart, M.J., and Cerion, R.A. 1995. Guanine nucleotide exchange catalyzed by dbl oncogene product. In *"Method in Enzymology"* (Balch, W.E., Der, C.J. and Hall, A., ed) 256:77-84.
- Zhang, Z., Devarajan, P., Dorfman, A. L., and Morrow J. S. 1998. Structure of the ankyrin-binding domain of α -Na, K-ATPase. *J. Biol. Chem.* 273, 18681-18684.
- Zhu, D. and L.Y.W. Bourguignon. 1998. The ankyrin-binding domain of CD44s is involved in regulating hyaluronic acid-mediated functions and prostate tumor cell transformation. *Cell Motility and the Cytoskeleton* 39:209-222.
- Zhu, D. and L.Y.W. Bourguignon. 2000. Interaction between CD44 and the repeat domain of ankyrin promotes hyaluronic acid-mediated ovarian tumor cell migration. *J. Cell Physiol.* 183:182-195.

APPENDICES:

Table 1: Binding of ^{125}I -labeled cytoskeletal proteins to synthetic peptides.

A: Binding To "GEGTDAVKRSL" (The sequence between aa717 and aa727 of Tiam1):

	<u>(nM x CPM Bound)</u>
^{125}I -labeled Intact Ankyrin	$15,260 \pm 120$
^{125}I -labeled ARD	$14,560 \pm 105$
^{125}I -labeled Ankyrin's Spectrin Binding Domain	770 ± 22
^{125}I -labeled Spectrin	850 ± 34

B: Binding To "GRATLEGSDKV" (The scrambled sequence):

	<u>(nM x CPM Bound)</u>
^{125}I -labeled Ankyrin	$1,020 \pm 36$
^{125}I -labeled ARD	920 ± 29
^{125}I -labeled Ankyrin's Spectrin Binding Domain	901 ± 24
^{125}I -labeled Spectrin	996 ± 27

C: Binding To "GTIKRAPFLGP" (The sequence between aa399 and aa409 of Tiam1)

	<u>(nM x CPM Bound)</u>
^{125}I -labeled Ankyrin	899 ± 23
^{125}I -labeled ARD	854 ± 17
^{125}I -labeled Ankyrin's Spectrin Binding Domain of	842 ± 19
^{125}I -labeled Spectrin	863 ± 20

^{125}I -labeled cytoskeletal proteins [e.g. intact ankyrin (100ng) or ARD (100ng) or spectrin binding domain of ankyrin (100ng) or spectrin (100ng)] were incubated with nitrocellulose discs coated with either the synthetic peptide "GEGTDAVKRSL" (corresponding to the sequence between aa717 and aa727 of Tiam1) or the scrambled peptide "GRATLEGSDKV" or another Tiam1-related peptide "GTIKRAPFLGP" (corresponding to the sequence between aa399 and aa409 of Tiam1) at 4°C for 4h as described in the Materials and Methods. As a control, the radiolabelled ligands including ^{125}I -labeled ankyrin, ^{125}I -labeled ARD and ^{125}I -labeled spectrin were also incubated with uncoated beads to determine the binding observed due to the non-specific binding of various ligands. Non-specific binding which represented approximately 20% of the total binding, was always subtracted from the total binding.

Table 2: Measurement of Tumor Cell Invasion and Migration.**A: In vitro cell invasion:**

Cells	<u>Cell Invasion</u> ^a (% of Control) ^b	
	DMSO-treated control	Cytochalasin D-treated
Untransfected cells (control)	100	22
Vector-transfected cells	96	24
Tiam1 fragment cDNA-transfected cells	95	20
C1199 Tiam1 cDNA-transfected cells	155	50
C1199 Tiam1cDNA and Tiam1 fragment cDNA co-transfected cells	90	17


B: In vitro cell migration:

Cells	<u>Cell Migration</u> ^a (% of Control) ^b	
	DMSO-treated control	Cytochalasin D-treated
Untransfected cells (control)	100	20
Vector-transfected cells	98	23
Tiam1 fragment cDNA-transfected cells	93	22
C1199 Tiam1cDNA-transfected cells	158	55
C1199 Tiam1cDNA and Tiam1 fragment cDNA co-transfected cells	88	14

a: SP1 cells [$\approx 1 \times 10^4$ cells/well in phosphate buffered saline (PBS), pH 7.2] [in the presence or absence of 20 μ g/ml cytochalasin D (dissolved in DMSO) or DMSO alone] were placed in the upper chamber of the transwell unit. In some cases, SP1 cells were transfected with either HA-tagged C1199 Tiam1 cDNA or GFP-tagged Tiam1 fragment cDNA or HA-tagged C1199 Tiam1cDNA plus GFP-tagged Tiam1 fragment cDNA, or vector alone. After 18h incubation at 37°C in a humidified 95% air/5% CO₂ atmosphere, cells on the upper side of the filter were removed by wiping with a cotton swap. Cell migration processes were determined by measuring the cells that migrate to the lower side of the polycarbonate filters containing serum by standard cell number counting assays as described in the Materials and Methods. Each assay was set up in triplicate and repeated at least 3 times. All data were analyzed statistically by Student's t test and statistical significance was set at $p < 0.01$. In these experiments ≈ 30 to 40% of input cells ($\approx 1 \times 10^4$ cells/well) undergo in vitro cell invasion and migration in the control samples.

b: The values expressed in this table represent an average of triplicate determinations of 3-5 experiments with a standard deviation less than $\pm 5\%$.

FIGURE 1



Detection of Tiam1 expression in SP-1 cells or COS-7 transfectants.

SP-1 cells and COS-7 cells [transfected with the full-length Tiam1 cDNA (FL1591) or N-terminally truncated C1199 Tiam1 cDNA or vector alone] were solubilized in SDS sample buffer and analyzed by SDS-PAGE and immunoblot as described in the Materials and Methods.

Lane 1: Anti-Tiam1-mediated immunoblot of SP-1 cells.

Lane 2: Anti-Tiam1-mediated immunoblot of COS-7 cells transfected with the full-length Tiam1 cDNA (FL1591).


Lane 3: Anti-Tiam1-mediated immunoblot of COS-7 cells transfected with the N-terminally truncated C1199 Tiam1 cDNA.

Lane 4: Immunoblot of SP-1 cells with preimmune rabbit serum.

Lane 5: Immunoblot of COS-7 cells [transfected with Tiam1 cDNA (FL1591)] with preimmune rabbit serum.

Lane 6: Immunoblot of COS-7 cells [transfected with the N-terminally truncated C1199 Tiam1 cDNA] with preimmune rabbit serum.

FIGURE 2




Tiam1-mediated GDP/GTP exchange for RhoGTPases.

Purified *E. coli*-derived GST-tagged GTPases (e.g. Rac1, Cdc42 or RhoA) were preloaded with GDP. First, 2pmole Tiam1 isolated from SP1 cells or COS-7 transfectants was added to the reaction buffer containing 20mM Tris-HCl (pH 8.0), 100mM NaCl, 10mM MgCl₂, 100uM AMP-PNP, 0.5 mg/ml bovine serum albumin, and 2.5μM GTP γ ³⁵S (\approx 1,250Ci/mmol). Subsequently, 2.5pmole GDP-loaded GST-tagged RhoGTPases (e.g. Rac1, Rac1, Cdc42 or GST alone) were mixed with the reaction buffer containing Tiam1 and GTP γ ³⁵S to initiate the exchange reaction at room temperature. At various time points, the reaction of each sample was terminated by adding ice-cold termination buffer as described in the Materials and Methods. The termination reactions were then filtered immediately through nitrocellulose filters, and the radioactivity associated with the filters were measured by scintillation fluid. The amount of GTP γ ³⁵S bound to Tiam1 or control sample (preimmune serum-conjugated Sepharose beads) in the absence of RhoGTPases (e.g. Rac1, Cdc42 or RhoA) was subtracted from the original values. Data represent an average of triplicates from 3-5 experiments. The standard deviation was less than 5%.

A: Kinetics of GTP γ ³⁵S bound to GDP-loaded GST-Rac1 (a), GST-Cdc42 (b) or GST-RhoA (c) or GST alone (d) in the presence of Tiam1 (isolated from SP-1 cells).

B: The maximal level of GTP γ ³⁵S bound to GST-Rac1 in the presence of Tiam1 isolated from SP1 grown in 5% fetal calf serum (a-shaded bar) or 20% fetal calf serum (a-blank bar); or the full-length Tiam1 (1591) isolated from COS-7 transfectants grown in 5% fetal calf serum (b-shaded bar) or 20% fetal calf serum (b-blank bar); or the C1199 Tiam1 isolated from COS-7 transfectants grown in 5% fetal calf serum (c-shaded bar) or 20% fetal calf serum (c-blank bar); or Tiam1 isolated from vector-transfected COS-7 cells grown in 5% fetal calf serum (d-shaded bar) or 20% fetal calf serum (d-blank bar).

FIGURE 3



Detection of Tiam1-ankyrin complex in SP1 cells.

SP1 cells (5×10^5 cells) were solubilized by 1% Nonidet P-40 (NP-40) buffer and processed for anti-ankyrin or anti-Tiam1-mediated immunoprecipitation followed by immunoblotting with anti-Tiam1 or anti-ANK1 (or anti-ANK3) antibody, respectively as described in the Materials and Methods.

A: Analysis of Tiam1-ANK1 complex:

Lane 1: Anti-ANK1-mediated immunoprecipitation followed by immunoblotting with rabbit preimmune serum.

Lane 2-3: Detection of Tiam1 in the complex by mouse anti-ANK1-mediated immunoprecipitation followed by immunoblotting with rabbit anti-Tiam1 antibody (lane 2) or reblotting with mouse anti-ANK-1 antibody (lane 3).

Lane 4-7: Detection of ANK1 in the complex by rabbit anti-Tiam1-mediated immunoprecipitation followed by immunoblotting with mouse anti-ANK1 antibody (lane 4) or reblotting with rabbit anti-Tiam1 antibody (lane 5); or peroxidase conjugated normal mouse IgG (lane 6) or peroxidase conjugated rabbit preimmune IgG (lane 7).


B: Analysis of Tiam1-ANK3 complex:

Lane 1: Anti-ANK3-mediated immunoprecipitation followed by immunoblotting with rabbit preimmune serum.

Lane 2-3: Detection of Tiam1 in the complex by mouse anti-ANK3-mediated immunoprecipitation followed by immunoblotting with rabbit anti-Tiam1 antibody (lane 2) or reblotting with mouse anti-ANK-3 antibody (lane 3).

Lane 4-7: Detection of ANK3 in the complex by rabbit anti-Tiam1-mediated immunoprecipitation followed by immunoblotting with mouse anti-ANK3 antibody (lane 4) or reblotting with rabbit anti-Tiam1 antibody (lane 5); or peroxidase conjugated normal mouse IgG (lane 6) or peroxidase conjugated rabbit preimmune IgG (lane 7).

FIGURE 4




Binding interaction between Tiam1 and the cytoskeletal protein, ankyrin.

A: Tiam1 (isolated from SP-1 cells) bound to the anti-Tiam1 immuno-beads were incubated with 125 I-labeled ankyrin (5,000 cpm/ng protein) in the absence (a) or the presence of 100-fold excess of unlabeled ankyrin (b) or spectrin (c). Following binding, the immunobeads were washed extensively in binding buffer and the bead-bound radioactivity was estimated.

B: Autoradiogram of 125 I-labeled ankyrin binding to a polyacrylamide gel containing purified Tiam1 (isolated from SP-1 cells) in the absence (a) or the presence of 100-fold excess of unlabeled ankyrin (b) or spectrin (c).

FIGURE 5



Ankyrin structure and ankyrin repeat domain (ARD) fusion protein.

A-a: Schematic illustration of functional domains in ankyrin full length: ankyrin repeat domain (ARD), spectrin binding domain (SBD) and regulatory domain (RD).

A-b: ARD cDNA was constructed according to the strategy described in the Materials and Methods. This ARD cDNA construct encodes for the N-terminal region of the ankyrin membrane binding domain with a tandem array of 24 ankyrin repeats.


B: A coomassie blue staining of the 116kDa GST-ARD fusion protein purified by affinity column chromatography (lane 1); and the 89kDa ARD (lane 2) after the removal of GST by thrombin digestion.

C and D: Scatchard plot analyses of the equilibrium binding between 125 I-labeled ankyrin and Tiam1.

Various concentrations of 125 I-labeled ankyrin [e.g. intact erythrocyte ankyrin (ANK1) or ARD] were incubated with purified Tiam1-coupled beads at 4°C for 4 h. Following binding, beads were washed extensively in binding buffer and the beads-bound radioactivity was counted. As a control, 125 I-labeled ankyrin or 125 I-labeled ARD was also incubated with uncoated beads to determine the binding observed due to the non-specific binding of various ligands. Non-specific binding which represented approximately 20% of the total binding, was always subtracted from the total binding. Our binding data are highly reproducible. The values expressed in the result section represent an average of triplicate determinations of 3-5 experiments with a standard deviation less than $\pm 5\%$.

Scatchard plot analysis of the equilibrium binding data between 125 I-labeled intact erythrocyte ankyrin (ANK1) and Tiam1 (C); and Scatchard plot analysis of the equilibrium binding data between 125 I-labeled ARD and Tiam1 (D).

FIGURE 6



Properties of Tiam1 and Tiam1 mutant proteins.

A-a: The full length Tiam1 contains DH, dbl-homology domain; DHR, discs-large homology domain; two pleckstrin homology (PH) domains [including the NH₂-terminal PH (PHn) and the COOH-terminal PH (PHc)].

A-b: The N-terminally truncated C1199 Tiam1 encodes the C-terminal 1199 amino acids.

A-c: The Tiam1 fragment encodes the sequence between aa393-aa738.

B: Characterization of Tiam1 fragment (aa393-aa738) fusion proteins.

Coomassie blue staining of *E. coli*-derived CBP-Tiam1 fragment fusion protein purified by calmodulin affinity column chromatography (lane 1); and GFP-tagged Tiam1 fragment fusion purified by anti-GFP-conjugated affinity column chromatography (lane 2).

C-a: Binding of 125 I-Tiam1 fragment to ankyrin.

C-b: Binding of 125 I-Tiam1 fragment to ARD.

C-c: Binding of 125 I-Tiam1 fragment to ankyrin's spectrin binding domain.

C-d: Binding of 125 I-Tiam1 fragment to spectrin.


D and E: Binding analysis between GST-ARD and the recombinant C1199 Tiam1 *in vitro*.

In each reaction, 15-60 μ l of glutathione-Sepharose bead slurry containing GST-ARD or GST alone was suspended in 0.5 ml of binding buffer [20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.1% bovine serum albumin and 0.05% Triton X-100]. Purified C1199 Tiam1 (0.5 μ g-1.0 μ g) was then added to the bead suspension in the absence or the presence of an excess amount of CBP-tagged Tiam1 fragment (100 μ g) at 4°C for 4 h. Following binding, the GST fusion protein was eluted with its associated C1199 Tiam1 using 150 μ l of 50mM Tris-HCl (pH 8.0) buffer containing 30mM glutathione. The amount of eluted GST fusion protein and C1199 Tiam1 was then determined by SDS-PAGE and Coomassie blue staining followed by densitometric scanning using a software NIH Image V1.54. The amount of ARD (mol) per C1199Tiam1 (mol) was then calculated. Values represent relative binding abilities averaged from three experiments \pm SEM.

D: The amount of C1199Tiam1 (mol) associated with GST-ARD (mol) was measured in the absence (lane 1) or the presence of recombinant Tiam1 fragment (lane 2) or C1199 Tiam1 associated with GST-coated beads (lane 3) using SDS-PAGE and Coomassie blue staining followed by densitometric analyses.

E: Coomassie blue staining of C1199Tiam1 associated with GST-ARD in the absence (lane 1) or the presence of recombinant Tiam1 fragment (lane 2) or C1199 Tiam1 associated with GST-coated beads (lane 3).

FIGURE 7



Identification of the ankyrin binding domain of Tiam1.

A: 125 I-labeled Tiam1 was incubated with ankyrin-coated beads in the presence of various concentrations of unlabeled synthetic peptide (GEGTDAVKRSL-corresponding to the sequence between aa717-aa727 of Tiam1) (c) or the scrambled sequence (GRATLEGSDKV) (a) or another Tiam1-related peptide (GTIKRAPFLGP) (corresponding to the sequence between aa399 and aa409 of Tiam1) (b) as described in the Materials and Methods. The specific binding observed in the absence of any of the competing peptides is designated as 100%. The results represent an average of duplicate determinations for each concentration of the competing peptide used.


B: Schematic illustration of the *in vitro* mutagenesis approach used in this study.

Both C1199 Tiam1 (a) and C1199Tiam1Δ717-727 (lacking the sequence between aa717-aa727) (b) were constructed according to the strategy described in the Materials and Methods.

C: Anti-HA-mediated Immunoblot of SP-1 cells transiently transfected with vector alone (lane 1) or HA-tagged C1199 Tiam1 cDNA (lane 2) or HA-tagged C1199Tiam1Δ717-727 cDNA (lane 3).

D: The amount of 125 I-ankyrin binding to anti-HA immunoprecipitated materials isolated from SP-1 cells transfected with vector alone (a), or HA-tagged C1199Tiam1 cDNA (b) or HA-tagged C1199Tiam1Δ717-727 cDNA (c).


FIGURE 8



Stimulation of Tiam1-catalysed GDP/GTP exchange activity by ankyrin.

Purified *E. coli*-derived GST-tagged GTPases (e.g. Rac1, Cdc42 or RhoA) was preloaded with GDP. Subsequently, 2pmole of Tiam1 [isolated from untransfected or transfected cells according to the procedures described above] was preincubated with no ankyrin or ankyrin [e.g. intact ankyrin or ARD (1μg/ml)] followed by adding to the reaction buffer containing 20mM Tris-HCl (pH 8.0), 100mM NaCl, 10mM MgCl₂, 100μM AMP-PNP, 0.5 mg/ml bovine serum albumin, and 2.5μM GTPγ³⁵S (≈1,250Ci/mmol). Subsequently, 2.5pmole GDP-loaded GST-tagged RhoGTPases (e.g. Rac1, Rac1 or Cdc42) were mixed with the reaction buffer containing Tiam1 and GTPγ³⁵S to initiate the exchange reaction at room temperature. At various time points, the reaction of each sample was terminated by adding ice-cold termination buffer containing 20mM Tris-HCl (pH 8.0), 100mM NaCl, and 10 mM MgCl₂ as described in the Materials and Methods. The termination reactions were then filtered immediately through nitrocellulose filters, and the radioactivity associated with the filters were measured by scintillation fluid. The amount of GTPγ³⁵S bound to Tiam1 or control sample (preimmune serum-conjugated Sepharose beads) in the absence of RhoGTPases (e.g. Rac1, Cdc42 or RhoA) was subtracted from the original values. Data represent an average of triplicates from 3-5 experiments. The standard deviation was less than 5%. A-C: Kinetics of GTPγ³⁵S bound to GDP-loaded GST-Rac1 by Tiam1 (isolated from SP-1 cells) in the absence (C) or in the presence of ankyrin [e.g. intact erythrocyte ankyrin (ANK1) (A) or ARD fragment (B)].


FIGURE 9



Transfection of SP1 cells with HA-tagged C1199 Tiam1 cDNA (A) or GFP-tagged Tiam1 fragment cDNA (B) or co-transfection of HA-tagged C1199 Tiam1 cDNA and GFP-tagged Tiam1 fragment cDNA (C).

Detection of C1199 Tiam1 expression by anti-HA-mediated immunoblot in HA-tagged C1199 Tiam1 cDNA transfected cells (lane B-a) or in vector-transfected cells (lane A-a); Detection of Tiam1 fragment expression by anti-GFP-mediated immunoblot in GFP-tagged Tiam1 fragment cDNA transfected cells (lane C-b) or vector-transfected cells (lane A-b); Detection of co-expression of C1199 Tiam1 and Tiam1 fragment by immunoblotting of cells (co-transfected with HA-tagged C1199 Tiam1 cDNA and GFP-tagged Tiam1 fragment cDNA) with anti-HA antibody (D-a) and anti-GFP antibody (D-b), respectively; In controls, no signal was detected in HA-tagged C1199 Tiam1 cDNA transfected cells or GFP-tagged Tiam1 fragment cDNA transfected cells using anti-GFP (lane B-b) or anti-HA (lane C-a)-mediated immunoblotting, respectively.

FIGUER 10



Double immunofluorescence staining of ankyrin and Tiam1 cDNA (e.g. C1199 Tiam1 cDNA or Tiam1 fragment cDNA)-transfected SP1 cells.

SP1 cells (transfected with HA-tagged C1199 Tiam1 cDNA or GFP-tagged Tiam1 fragment cDNA or co-transfected with HA-tagged C1199 Tiam1 cDNA plus GFP-tagged Tiam1 fragment cDNA) were fixed by 2% paraformaldehyde. Subsequently, cells were rendered permeable by ethanol treatment and stained with various immuno-reagents as described in the Materials and Methods.

A, B and C: Rh-labeled anti-ANK3 staining (A), FITC-anti-Tiam1 staining (B) and co-localization of ankyrin and Tiam1 (C) in untransfected SP1 cells.

D, E and F: Rh-labeled anti-ANK3 staining (D), FITC-anti-HA-labeled C1199 Tiam1 staining (E), and co-localization of ankyrin and C1199 Tiam1 (F) in HA-tagged C1199 Tiam1 cDNA transfected SP1 cells.


G, H and I: Rh-labeled anti-ANK3 staining (G), GFP-tagged Tiam1 fragment (H) and co-localization of ankyrin and Tiam1 fragment (I) in GFP-tagged Tiam1 fragment cDNA transfected SP1 cells.

a, b and c: Rh-labeled preimmune IgG staining (a), GFP-tagged Tiam1 fragment (b) and co-localization of preimmune IgG and Tiam1 fragment (c) in GFP-tagged Tiam1 fragment cDNA transfected SP1 cells.

J, K and L: Rh-labeled anti-HA staining of C1199 Tiam1 (J), GFP-tagged Tiam1 fragment (K) and co-localization of C1199 and Tiam1 fragment (L) in SP1 cells co-transfected with HA-tagged C1199 cDNA and GFP-tagged Tiam1 fragment cDNA.

d, e and f: Rh-labeled anti-ANK3 staining (d), GFP-tagged Tiam1 fragment (e) and co-localization of ankyrin and Tiam1 fragment (f) in SP1 cells co-transfected with HA-tagged C1199 cDNA and GFP-tagged Tiam1 fragment cDNA.

FIGUER 11



Kinetics of $GTP\gamma^{35}S$ bound to GDP-loaded GST-Rac1 in the presence of ankyrin-associated Tiam1 isolated from SP-1 cells [transfected with HA-tagged C1199 Tiam1 cDNA (a) or GFP-tagged Tiam1 fragment cDNA (d) or co-transfected with HA-tagged C1199 Tiam1 cDNA plus GFP-tagged Tiam1 fragment cDNA (c) or vector alone (b)].

Purified *E. coli*-derived GST-tagged GTPases (e.g. Rac1, Cdc42 or RhoA) were preloaded with GDP. First, 2pmole ankyrin-associated Tiam1 isolated from various SP1 transfectants was added to the reaction buffer containing 20mM Tris-HCl (pH 8.0), 100mM NaCl, 10mM $MgCl_2$, 100uM AMP-PNP, 0.5 mg/ml bovine serum albumin, and 2.5uM $GTP\gamma^{35}S$ ($\approx 1,250$ Ci/mmol). Subsequently, 2.5pmole GDP-loaded GST-tagged RhoGTPases (e.g. Rac1, Rac1, Cdc42 or GST alone) were mixed with the reaction buffer containing ankyrin-associated Tiam1 and $GTP\gamma^{35}S$ to initiate the exchange reaction at room temperature. At various time points, the reaction of each sample was terminated by adding ice-cold termination buffer as described in the Materials and Methods. The termination reactions were then filtered immediately through nitrocellulose filters, and the radioactivity associated with the filters were measured by scintillation fluid. The amount of $GTP\gamma^{35}S$ bound to Tiam1 or control sample (preimmune serum-conjugated Sepharose beads) in the absence of RhoGTPases (e.g. Rac1, Cdc42 or RhoA) was subtracted from the original values. Data represent an average of triplicates from 3-5 experiments. The standard deviation was less than 5%.

BINDING: We have prepared the report according to the instruction provided by DOD.

FINAL REPORTS:

Paper Publications:

1. Iida, N. and Lilly Y.W. Bourguignon. Coexpression of CD44 Variant (v10/ex 14) and CD44s in Human Mammary Epithelial Cells Promotes Tumorigenesis. *J. Cell Physiol.* 171:152-160 (1997).
2. Bourguignon, Lilly Y.W., H.B. Zhu, A. Chu, L. Zhang and Mien-Chie Hung. Interaction Between the Adhesion Receptor, CD44 and the Oncogene Product, p185^{HER2}, Promotes Human Ovarian Tumor Cell Activation. *J. Biol. Chem.* 272:27913-27918 (1997).
3. Bourguignon, Lilly Y.W., Role of Membrane-Associated Cytoskeleton In Regulating Immune Cell Function Membrane Skeleton Linker Proteins In Immune Cells. In "Encyclopedia of Immunology". (I.M. Roitt and P.J. Delves, eds.), Academic Press, (1997)(Invited Review Article).
4. Huang, A. J., C.H. Li, Y. W. Chen and Lilly Y. W. Bourguignon. Co-expression of bcl-2 and CD44s in Basal Layers of Human Ocular Surface Epithelia. *Adv. Exp. Med. Biol.* 438:527-531 (1998).
6. Zhu, D. and Lilly Y. W. Bourguignon. The Ankyrin-Binding Domain Of CD44s Is Involved In Regulating Hyaluronic Acid-Mediated Function And Prostate Tumor Cell Transformation. *Cell Motility & Cytoskeleton* 39:209-222 (1998).
7. Bourguignon, Lilly Y. W., Z. Gunja-Smith, N. Iida, H. B. Zhu, L.J.T. Young, W. Muller and R. D. Cardiff. CD44^{v3,8-10}-Cytoskeleton Interaction Is Involved In Matrix Metalloproteinase (MMP-9) Function And Tumor Cell Migration & Invasion In Metastatic Breast Tumor Cells. *J. Cell. Physiol.* 176:206-215 (1998)
8. Kalish, E., N. Iida, F.L. Moffat and Lilly Y. W. Bourguignon. A New CD44v3-Containing Isoform Is Involved in Tumor Cell Migration and Human Breast Cancer Progression. *Front Biosci.* 4:1-8 (1999).
9. Ameen, N.A., B. Martensson, Lilly Y. W. Bourguignon, C. Marino, J. Isenberg and G.E. McLaughlin. CFTR Channel Insertion to The Apical Surface In Rat Duodenal Villus Epithelial Cell Is Upregulated By VIP In Vivo. *J. Cell Sci.* 112:887-894 (1999).
10. Bourguignon, Lilly Y.W., H.Zhu, L. Shao, D. Zhu and Y.W.Chen, Rho-Kinase (ROK) Promotes CD44^{v3,8-10}-Ankyrin Interaction And Tumor Cell Migration In Metastatic Breast Cancer Cells. *Cell Motility & The Cytoskeleton*, 43:269-287 (1999).
11. Bourguignon, Lilly Y.W., H.Zhu, L. Shao and Y.W.Chen, CD44 Interaction with Tiam1 Promotes Rac1 Signaling and Hyaluronic Acid (HA)-Mediated Breast Tumor Cell Migration. *J. Biol. Chem.* 275:1829-1838 (2000).

12. Zhu, D. and Lilly Y.W. Bourguignon. Interaction Between CD44 and The Repeat Domain of Ankyrin Promotes Hyaluronic Acid (HA)-Mediated Ovarian Tumor Cell Migration. *J. Cell Physiol.* 183:182-195 (2000).

13. Diaz, F. and Lilly Y.W. Bourguignon. Selective Down-Regulation of IP3 Receptor Subtypes By Caspases and Calpain During TNF α -Induced Apoptosis of Human T-Lymphoblasts. (*Cell Calcium*, In Press, 2000).

14. Bourguignon, Lilly Y.W., H.Zhu, L. Shao and Y.W.Chen, Ankyrin-Tiam1 Interaction Promotes Rac1 Signaling and Metastatic Breast Tumor Cell Invasion and Migration. (*J. Cell Biol.*, In Press, 2000).

Abstracts:

1. Dan Zhu and Lilly Y. W. Bourguignon. The Ankyrin-Binding Domain Of CD44s Is Required For Cell Adhesion, Src Kinase Association And Proliferation In Human Prostate Tumor Cells. *Proceeding of the American Association for Cancer Res.* 38:532 (1997).

2. Bourguignon, Lilly Y. W., Z. Gunja-Smith, N. Iida, H. B. Zhu, L.J.T. Young and R. D. Cardiff. CD44v3 Is Responsible For Vascular Growth Factor (VEFG) Binding, Membrane-Cytoskeleton Interaction, and Matrix Metalloproteinase (MMP) Activation In Metastatic Breast Tumor Cells. *Proceeding of the American Association for Cancer Res.* 38:532 (1997).

3. Kalish, E., N. Iida, F.L. Moffat and Lilly Y. W. Bourguignon. A New CD44 Variant Is Associated With the Progression of Human Breast Carcinoma. *Proceeding of the American Association for Cancer Res.* 38:66 (1997).

4. Bourguignon, Lilly Y.W., H.B. Zhu, A. Chu, N. Iida, L. Zhang and Mien-Chie Hung. Interaction Between CD44 and p185^{neu} Promotes Human Ovarian Tumor Cell Activation. *Mol. Biol. Cell* 8:360a (1997).

5. Bourguignon, Lilly Y.W., H.B. Zhu, N. Iida and L.J.Shao. The Cytoplasmic Deletion (Dominant-Negative) Mutant of CD44s Down-regulates Hyaluronan-Mediated Tiam1-RhoA Signaling and IL-8 gene Activation In Human Mammary Epithelial Cells. *Mol. Biol. Cell* 9:301a (1998).

6. Diaz, F. and Lilly Y.W. Bourguignon. IP3 Receptor Subtypes Are Cellular Targets for TNF α -Induced Caspases During Apoptosis of Human T-Lymphoblasts. *Mol. Biol. Cell* 9:250a (1998).

7. Singleton, P.A. and Bourguignon, Lilly Y.W. Identification of A Novel Plasma Membrane-associated High Molecular Weight IP3 Receptor In Human T-Lymphocytes. *Mol. Biol. Cell* 9:250a (1998).

8. Bourguignon, Lilly Y.W., H.Zhu, L. Shao, and Y.W.Chen, Identification Of An Ankyrin-Binding Domain In TIAM1 And Its Role In Regulating CD44v_{3,8-10}-Associated Metastatic Breast Tumor Cell Invasion And Migration. *Proceeding of the American Association for Cancer Res.* 40:196 (1999).

9. Bourguignon, Lilly Y.W., H.Zhu, L. Shao, D. Zhu and Y.W.Chen, Rho-Kinase (ROK) Promotes CD44^{v3,8-10}-Ankyrin Interaction And Tumor Cell Migration In Metastatic Breast Cancer Cells. Proceeding of the American Association for Cancer Res. 40:105 (1999).

10. Zhu, D. and Lilly Y.W. Bourguignon. Interaction Between CD44 and The Repeat Domain of Ankyrin Promotes Hyaluronic Acid (HA)-Mediated Ovarian Tumor Cell Migration. Proceeding of the American Association for Cancer Res. (2000).

11. Bourguignon, Lilly Y.W., H.Zhu, L. Shao and Y.W.Chen, CD44 Interaction with Tiam1 Promotes Rac1 Signaling and Hyaluronic Acid (HA)-Mediated Breast Tumor Cell Migration. Proceeding of the American Association for Cancer Res. (2000).

A list of personnel:

Lilly Y.W. Bourguignon, Ph.D., Principal Investigator.

F. Diaz, Ph.D. Postdoctoral fellow.

D. Zhu, Ph.D. Research Associate.

H.B. Zhu, Technician.

L.J. Shao, Technician.